<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_uEU7Fcv">Challenges for the evaluation of digital health solutions-A call for innovative evidence generation approaches</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Chaohui</forename><surname>Guo</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Roche Diagnostics , Basel , Switzerland.</note>
								<orgName type="institution">Roche Diagnostics</orgName>
								<address>
									<settlement>Basel</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hutan</forename><surname>Ashrafian</surname></persName>
							<idno type="ORCID">0000-0003-1668-0672</idno>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Imperial College London , London , UK.</note>
								<orgName type="institution">Imperial College London</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Saira</forename><surname>Ghafur</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Imperial College London , London , UK.</note>
								<orgName type="institution">Imperial College London</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gianluca</forename><surname>Fontana</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Imperial College London , London , UK.</note>
								<orgName type="institution">Imperial College London</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Clarissa</forename><surname>Gardner</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Imperial College London , London , UK.</note>
								<orgName type="institution">Imperial College London</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Matthew</forename><surname>Prime</surname></persName>
							<email>matthew.prime.mp1@roche.com</email>
							<idno type="ORCID">0000-0001-8717-0130</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Roche Diagnostics , Basel , Switzerland.</note>
								<orgName type="institution">Roche Diagnostics</orgName>
								<address>
									<settlement>Basel</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<note type="raw_affiliation">Scripps Research Translational Institute Scripps Research Translational Institute</note>
								<orgName type="institution" key="instit1">Scripps Research Translational Institute</orgName>
								<orgName type="institution" key="instit2">Scripps Research Translational Institute</orgName>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_MJBVS7s">Challenges for the evaluation of digital health solutions-A call for innovative evidence generation approaches</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">4C00EDE9B302CF292370E2D2F11B0D2C</idno>
					<idno type="DOI">10.1038/s41746-020-00314-2</idno>
					<note type="submission">Received: 15 December 2019; Accepted: 22 July 2020;</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T05:47+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_f5A8Dk6"><p xml:id="_JMVdR6b"><s xml:id="_GDyTnwx">The field of digital health, and its meaning, has evolved rapidly over the last 20 years.</s><s xml:id="_8rQru6M">For this article we followed the most recent definition provided by FDA in 2020.</s><s xml:id="_jBcJTcw">Emerging solutions offers tremendous potential to positively transform the healthcare sector.</s><s xml:id="_tu2FdzE">Despite the growing number of applications, however, the evolution of methodologies to perform timely, cost-effective and robust evaluations have not kept pace.</s><s xml:id="_z9xPPhV">It remains an industry-wide challenge to provide credible evidence, therefore, hindering wider adoption.</s><s xml:id="_yjcXnKf">Conventional methodologies, such as clinical trials, have seldom been applied and more pragmatic approaches are needed.</s><s xml:id="_nHE8Vqf">In response, several academic centers such as researchers from the Institute of Global Health Innovation at Imperial College London have initiated a digital health clinical simulation test bed to explore new approaches for evidence gathering relevant to solution type and maturity.</s><s xml:id="_t4rEeMf">The aim of this article is to: (1) Review current research approaches and discuss their limitations; (2) Discuss challenges faced by different stakeholders in undertaking evaluations; and (3) Call for new approaches to facilitate the safe and responsible growth of the digital health sector.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="13" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="14" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_5bzP6bc">INTRODUCTION</head><p xml:id="_5hMSvdc"><s xml:id="_C7AxmWR">Digital health has evolved rapidly since the concept was first introduced in 2000 by Seth Frank <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b1">2</ref> .</s><s xml:id="_tFZ94Fc">The FDA considers digital health as a broad scope that includes categories such as mobile health, health information technology, wearable devices, telehealth and telemedicine, and personalized medicine 3 , a definition we follow in this article.</s><s xml:id="_zUVhYbK">Indeed, the numbers of digital health solutions are booming, for example, more than 300,000 health applications exist with more than 200 added daily <ref type="bibr" target="#b2">4</ref> .</s><s xml:id="_vfa9C4U">Digital solutions can be grouped as follows, based on potential risk to patients 5 : (1) Solutions that improve system efficiency but with no measurable patient outcome benefit; (2) Mobile digital health, that inform or deliver basic monitoring, and encourage behavior change and self-management; (3) Clinical decision support (CDS), and prediction models, that guide treatment, deliver active monitoring, calculate and/or diagnose.</s></p><p xml:id="_G5egB3C"><s xml:id="_4Yexkcg">The evidence requirements of regulators are determined by a product's intended use claims, as such, a large proportion of digital health solutions (e.g.</s><s xml:id="_JySVeS5">administrative tools and wellness apps) fall outside of their jurisdiction.</s><s xml:id="_pav5Dqv">Therefore, a huge challenge for end users, such as patients and providers (e.g.</s><s xml:id="_xn63psu">healthcare professionals, hospital administrators), is how to determine a new solution's credibility and compliance with standards.</s><s xml:id="_7fbWGWS">Furthermore, end users have different thresholds for acceptance of innovation and can be grouped into five archetypes: innovators, early adopters, early majority, late majority, and laggards <ref type="bibr" target="#b3">6</ref> .</s><s xml:id="_8HDfaUc">In addition, aging adults, considered amongst the most digitally divided demographic group <ref type="bibr" target="#b4">7</ref> , present unique challenges and dedicated efforts exist to develop strategies for implementation <ref type="bibr" target="#b4">[7]</ref><ref type="bibr" target="#b5">[8]</ref><ref type="bibr" target="#b6">[9]</ref><ref type="bibr" target="#b7">[10]</ref> .</s><s xml:id="_kF2zYYk">Conversely, challenges exist for healthcare innovators to best demonstrate solution impacts and to ensure compliance with standards, these include: unclear end-user expectations; uncertainty of evidence generation approaches; and, keeping up to date with the evolving compliance landscapes.</s></p><p xml:id="_HyvRHwk"><s xml:id="_drRqvvT">This article discusses the challenges for providing timely and robust evidence, to meet end-user expectations, in the context of digital health solutions.</s><s xml:id="_R7H82Jm">Specifically, we consider how the cadence of traditional research approaches are misaligned with the "fail fast, fail often" mantra espoused by technology start-ups.</s><s xml:id="_2FjdN4k">In addition, we introduce clinical simulation-based research as a potential opportunity to bridge the evidence gap.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_KUyK7KS">A RAPIDLY EVOLVING GUIDANCE AND REGULATORY LANDSCAPE</head><p xml:id="_rBDyBWS"><s xml:id="_FXVyhE4">Over the last 10 years a plethora of guidance has been developed for digital health innovators.</s><s xml:id="_uH3548e">In Table <ref type="table" target="#tab_0">1</ref>, we highlighted 10 of the key guidance (e.g., Continua Design Guidelines 2010, WHO monitoring and evaluating digital health solutions 2016, NICE evidence standards framework 2019; US FDA pre-certification program-a working model 2019, and FDA Proposed Regulatory Framework for modifications to Artificial intelligence/Machine learning-based Software as a Medical Device 2019).</s><s xml:id="_8X8ezDW">We ordered them by date first published and provided for each guidance a brief summary, applicable areas within digital health, releasing organization, and its main activities (Table <ref type="table" target="#tab_0">1</ref>).</s><s xml:id="_eQhBFpj">We observed that development of such documents follows a pattern: initial development by industry, optimization by non-government organizations, and finally refinement by government agencies.</s><s xml:id="_XJKjzBY">In addition, academic initiatives and institutions have produced critical thought leadership, often acting as counterbalance to industry proposals (Table <ref type="table" target="#tab_4">2</ref>; The digital health scorecard 2019).</s><s xml:id="_wCbawzj">In Table <ref type="table" target="#tab_4">2</ref>, we highlighted five academic recommendations relevant to undertaking evidence generation studies for digital health solutions.</s></p><p xml:id="_EgeauT2"><s xml:id="_Ku2TaAu">Until recently regulators relied upon modifications to existing medical device (software) regulations and innovators were encouraged to conform to development standards, as shown in Table <ref type="table" target="#tab_5">3</ref>, where we highlighted eight regulations and standards relevant to digital health solutions (e.g., IEC Medical device software, ISO Health informatics-requirements for an electronic health record architecture).</s><s xml:id="_MSenzpe">However, the speed of development, 99 Documents developed by the International Medical Device Regulators Forum (IMDRF) as the basis for SaMD regulatory efforts in various countries Software as a Medical Device (SaMD) 2017 International Medical Device Regulators Forum (IMDRF) The International Medical Device Regulators Forum (IMDRF) was conceived in February 2011 as a forum to discuss future directions in medical device regulatory harmonization.</s><s xml:id="_X4nqkxm">It is a voluntary group of medical device regulators from around the world who have come together to build on the strong foundational work of the Global Harmonization Task Force on Medical Devices (GHTF), and to accelerate international medical device regulatory harmonization and convergence.</s><s xml:id="_3YQbU7b">US FDA mobile medical apps guidance 12 Risk-based approach (not all mobile apps are subject to FDA regulation).</s><s xml:id="_nqEyYpj">The agency oversees most mobile apps that are intended to treat, diagnose, cure, mitigate, or prevent disease or other conditions as medical devices under federal statute.</s><s xml:id="_tuNAkKB">Mobile medical applications 2018 Food &amp; Drug Administration (FDA) The FDA is responsible for protecting and promoting public health throught the control and supervision, amongst other things, e.g., medical devices.</s></p><p xml:id="_C8nGvzY"><s xml:id="_vCwpkwN">Table 1 continued Document title Document descriptions Applicable areas within digital health Date first published Organization responsible Main activities of releasing organization Code of conduct for data-driven health and care technology 13 Provides 10 principles for developing and evaluating digital health solutions All digital health solutions 2019 UK Department of Health &amp; Social Care Responsible for policy on health and social care matters in England &amp; Wales NICE evidence standards framework 5</s></p><p xml:id="_agGhzxD"><s xml:id="_xHqRExu">Providing guidance on evidence generation for effectiveness standards (section A) and economic standards (section B).</s><s xml:id="_HNQG9ck">Guiding the user through identifying the functional classification of their product (threetier based on risk to users).</s><s xml:id="_XSAYSmC">For products with higher tier functions, the gold standard for evaluating their effectiveness is a high-quality intervention study or randomized controlled trial (RCT).</s></p><p xml:id="_euxusvS"><s xml:id="_k9rWG9t">Digital health solutions (excl.</s><s xml:id="_8xkPBAs">products with adaptive artificial intelligence algorithms) 2019 National Institute for Health and Care Excellence (NICE) Executive non-departmental public body of the Department of Health in the United Kingdom which publishes guidelines, amongst other things, the use of health technologies within the National Health Service (NHS)/ US FDA pre-certification program (a working model) 14 Provides a voluntary pathway for efficient oversight of software-based medical devices from manufacturers who have demonstrated a robust culture of quality and organizational excellence (CQOE) and are committed to monitoring real-world performance Low risk digital health solutions 2019 Food &amp; Drug Administration (FDA) The FDA is responsible for protecting and promoting public health throught the control and supervision, amongst other things, e.g., medical devices.</s><s xml:id="_8rQsjrU">Proposed Regulatory Framework for modifications to Artificial intelligence/Machine learningbased Software as a Medical Device (SaMD) 100 Proposed framework for modifications to AI/ML-based SaMD that is based on the internationally harmonized International Medical Device Regulators Forum (IMDRF) risk categorization principles, FDA's benefit-risk framework, risk management principles in the software modifications guidance, and the organization-based TPLC approach as envisioned in the Digital Health Software Precertification (Pre-Cert) Program.</s><s xml:id="_7Nd99qn">It also leverages practices from current premarket programs, including the 510(k), De Novo, and PMA pathways AI and ML algorithms-based solutions 2019 (draft document released for feedback) Food &amp; Drug Administration (FDA) The FDA is responsible for protecting and promoting public health throught the control and supervision, amongst other things, e.g., medical devices.</s></p><p xml:id="_UzBGUBx"><s xml:id="_aeuVvY3">diversity of interventions, and potential risks has finally prompted policy-makers to produce more targeted guidance on solution classification and evidence requirements 5,11-14 (Tables <ref type="table" target="#tab_0">1</ref> and <ref type="table" target="#tab_5">3</ref>).</s><s xml:id="_qAc5aDP">For example, one initiative, the FDA Pre-certification Program 14 , seeks to streamline the approval of Software as a Medical Device (SAMD), and proposes to assess both development organization and product capabilities.</s><s xml:id="_5UtJnxf">Notwithstanding, current guidance does not go far enough to enable innovators and end-users to know what evidence generation approaches are appropriate, and practical, for all classes of digital health solutions throughout the product lifecycle.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_g42eZek">TRADITIONAL APPROACHES TO EVALUATION OF DIGITAL HEALTH SOLUTIONS</head><p xml:id="_kspQeGG"><s xml:id="_hs9yXYK">The most commonly recognized evidence for healthcare interventions is the randomized controlled clinical trial (RCT) <ref type="bibr" target="#b9">15,</ref><ref type="bibr" target="#b10">16</ref> , yet, only a handful of products have been tested in this way as shown by recent systematic review <ref type="bibr" target="#b11">17</ref> and our searching results in Table <ref type="table" target="#tab_6">4</ref>, where we illustrated recent studies evaluating digital solutions and their methods (including study designs, study length, sample size, etc.).</s><s xml:id="_h4CMFfz">Indeed, a recent systematic review of publications between 1995 and 2016 identified just 24 RCTs for the high-risk CDS category <ref type="bibr" target="#b11">17</ref> .</s><s xml:id="_uJq3eVe">In our opinion, this lack of studies indicates that these methods are no longer practicable, likely due to the speed of digital product development and iterative upgrading.</s><s xml:id="_e4gEs3A">In Fig. <ref type="figure">1</ref>, we mapped existing approaches along two dimensions; strength of evidence and study duration, which demonstrated the current methodological gap to evidence needs and opportunity for more innovative and agile approaches.</s><s xml:id="_JkD9Dpa">In this section we highlight a few of the more common methodologies, discuss strengths and limitations, and provide examples of their application (Table <ref type="table" target="#tab_6">4</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Yj7QS3z">Surveys and interviews</head><p xml:id="_DmFTdJJ"><s xml:id="_Sbt2QrM">In the early stages of development innovators seek to establish product usability, feasibility, and efficacy 18 .</s><s xml:id="_2USq24w">Surveys and/or interviews are often employed, which are low-cost, efficient, scalable tools to collect attitudes, user experience, and suitability insights.</s></p><p xml:id="_jtqaKrb"><s xml:id="_MkHdxMQ">Commonly used methods include usability testing, user-center design, net promoter score survey (e.g. to rate likelihood to recommend a product), online surveys, and log-file data analyses (e.g. to evaluate how users interact with the digital solution) <ref type="bibr" target="#b12">19</ref> .</s><s xml:id="_ySj3wzn">Such approaches have been used to explore user views on the usefulness of digital storytelling <ref type="bibr" target="#b13">20</ref> , to assess a web-based network for MS patients <ref type="bibr" target="#b14">21</ref> , and to collect attitudes towards digital treatment for depression <ref type="bibr" target="#b15">22</ref> .</s><s xml:id="_trUH5Gy">Despite being common, few efforts are turned into peer-reviewed publications <ref type="bibr" target="#b12">19</ref> , likely because the main purpose was to generate insights for internal use (e.g.</s><s xml:id="_vR6jDrG">product development) or external customer communication (e.g.</s><s xml:id="_jGg5eAG">case studies, presentations), and can be challenging to pass the peer-review for such work due to its relatively lower evidence strength <ref type="bibr" target="#b12">19,</ref><ref type="bibr" target="#b16">23</ref> .</s></p><p xml:id="_aZXjVKu"><s xml:id="_vtR3qyS">A key approach for digital solution development is usability testing which has been widely utilized to examine whether specified users can achieve intended use effectively and efficiently <ref type="bibr" target="#b17">[24]</ref><ref type="bibr" target="#b18">[25]</ref><ref type="bibr" target="#b19">[26]</ref> .</s><s xml:id="_ERWatSp">Typically, an intended user completes tasks and is observed for where they encounter problems.</s><s xml:id="_47MSjeY">This can be exploratory, to identify new features or functionalities, or comparative testing A vs. B <ref type="bibr" target="#b20">27,</ref><ref type="bibr" target="#b21">28</ref> .</s><s xml:id="_VyqbBeN">Studies are conducted by UX researchers, who synthesize results and translate to actions (e.g.</s><s xml:id="_Cknfqvc">product improvements).</s><s xml:id="_NGrjMrr">Data collected can be qualitative (e.g.</s><s xml:id="_NBChvSs">observations of problems) and/or quantitative (e.g.</s><s xml:id="_X9S4kKT">task time, task success rates).</s><s xml:id="_VxuebcD">Evidence strength depends upon study design, for example, task-based and controlled studies that collect quantitative data and can be replicated in other settings/sites, generate stronger evidence, whilst surveys and self-reported behaviors provide weaker evidence, as suggested by UX practitioners <ref type="bibr">29</ref> .</s><s xml:id="_mPbYMQV">Controversy exists regarding the appropriate number of participants.</s><s xml:id="_ZACKBDv">Whilst there is no "single correct number", for formative testing 5 participants is common ("the magic number 5"), compared with 20 participants for summative tests, which offer a tighter confidence interval <ref type="bibr" target="#b22">30</ref> .</s><s xml:id="_uYz3br8">Table 4 continued Evaluation approach Digital solution details Sample size Number of sites involved during evaluation Study length arm, 12-week, clusterrandomized study Prospective: Microrandomization design HeartSteps, an mHealth intervention that encourages regular walking via activity suggestions tailored to the individuals' current context 52 A micro-randomized trial to evaluate the efficacy of HeartSteps' activity suggestions to optimize the intervention; Contextually tailored suggestions could be delivered up to five times per day at user-selected times, for each participant on each day of the study, HeartSteps randomized whether to provide an activity suggestion, and, if so, whether to provide a walking or an antisedentary suggestion 44 adults were recruited Single Recruitment took place from August 2015 to January 2016; study conduction took 6 weeks; in total it took 4 years from recruitmnt (2015) to publishment (2019) Prospective: Pre-post intervention design Clinical decision support system to aid computerized physician order entry of chemotherapy order (C-CO) 117 Computerized chemotherpay order (C-CO) versus paper based chemotherapy order (P-CO) in a 30bed chemotherapy bay of a tertiary hospital.</s><s xml:id="_3VPnY4J">9279 chemotherapy orders from patients Single Not reported Computerized provider order entry (CPOE) 118 CPOE system was implemented throughout the hospital, and impacts (e.g., active order number, medication-related patient safety events) were measured 212 medication-related events Single Not reported Prospective: computational simulation A deep-learning framework (Med3R) as clinical decision support 119 Evaluating a deep-learning framework (Med3R), which utilizes a human-like learning and reasoning process, its performance was measured against general human examinees and similar leading product (i.e., WatsonQA system) in mocked written test of National Medical Licensing Examination in China Before officially taking National Medical Licence Examination for China (NMLEC) 7 practice tests were undertaken by Med3R to evaluate performance.</s><s xml:id="_Hbvzv8J">In 2017 the Med3R system was officially entered as a "special examineee" and succesfully passed with a score of 78%.</s><s xml:id="_NrxMYry">Multi Not reported Direct order entry by physicians into computer-based medical information systems 81 A computer simulation model was developed to represent the process through which medical orders are entered into a digital hospital information system and estimate the impacts on process improvement, reduction of errors, and improved communication etc.</s><s xml:id="_QDSH2yX">No participant was involved for realtime; instead, four weeks of patient data were extracted from the information system; 227 simulations of order entry were conducted Single Simulation itself took 16 h; end-toend timeline not reported Prospective: Clinical simulation A CDS tool that embedded clinical prediction rules into primary care workflow in EMR systems 90 Physicians interacting with video clips of standardized trained patient actors enacting the clinical scenarios (Pneumonia and Strep cases) 8 (3 resident and 5 faculty providers) in the clinical simulation phase Single Not reported Enhanced electronic health records system with features Physicians randomly assigned to baseline EHR or enhanced EHR; cognitive load for physicians and 38 (20 in baseline, 18 in intervention) Single 9 months (2016 April-Dec)</s></p><p xml:id="_M6GX3MB"><s xml:id="_rZkURWs">Table 4 continued Evaluation approach Digital solution Design/method details Sample size of sites involved during evaluation Study length such as automatic sorting and decision support instructions 91 performMazurance were evaluated for each condition Medication management system known as "Patient Safety through Intelligent Procedure in Medication" (PSIP-DK) 120 Physicians randomly assigned to baseline (local standard mangement system) or the new system (PSIP-DK); participating doctors were asked to perform a ward round on the five patients; impact on medical safefy were evaluated based on semistructural interviews 15 (10 doctors and 5 patients) and 50 simulation runs-25 using PSIP-DK and 25 using standard system Single 6+ months CDSS with weight-loss prediction model 121 Physicians with varying experience levels were then recruited to evaluate 100 patients in an independent validation data set of head and neck cancer twice (i.e., a pre-post design) 4 physicians evaluating 100 patient cases Single Not reported Voice assistants (recognition of commonly dispensed medications) 122 Voice recordings of 46 participants were played to voice assistants (e.g., Alexa, google assitant, siri) and compare the recognition accuracy rates 46 participants (voice recorded as stimuli) Single 2+ months (All voice recordings were analyzed between mid-December 2018 and mid-January 2019-end-to-end study length not reported) Retrospective (incl.</s><s xml:id="_GqTptZY">hybrid with prospective) Watson for Oncology 67 Treatment recommendations made by WFO (638 breast cancers) and the tumor board were compared to evaluate the concordance in hospitals of India 638 breast cancer patients Not applicable/ reported 2 years (2016-2018) Electronic symptom screening assessment scale (ESAS) 123 Retrospective chart reviews on cancer patient visits at a regional cancer centeremote and/or distributedr to examine whether patient visits with higher ESAS symptom scores are associated with higher rates of symptom documented in the chart and symptom-specific actions being taken 912 visits were identified Single Study length not reported</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Bd7xXrW">Prospective studies</head><p xml:id="_xtujnSU"><s xml:id="_heEHfuh">Prospective RCTs are the most accepted method for healthcare interventions <ref type="bibr" target="#b23">31</ref> .</s><s xml:id="_7CtG6D8">For end-users, not considered "early adopters", such studies are critical to justify adoption decisions.</s></p><p xml:id="_AUGccmN"><s xml:id="_6MWAygS">The randomization unit can be individuals, groups ("clusters"), or even specific solution components <ref type="bibr" target="#b24">32</ref> .</s><s xml:id="_t2r2Xtw">Choice of the study designs heavily depends on the digital solution and objectives of the evaluation.</s><s xml:id="_Frsv6vT">Individual-randomization trials (IRTs) are well-suited for digital solutions targeting an individual user, such as patient-level randomization (e.g.</s><s xml:id="_DGKbbrk">symptom self-monitoring <ref type="bibr" target="#b25">33</ref> ) or clinician-level randomization (e.g.</s><s xml:id="_DHQQwy9">digital pathology algorithms for pathologists <ref type="bibr" target="#b26">34</ref> ).</s><s xml:id="_7xjv59g">This is traditionally the most commonly used experimental design in healthcare research (e.g., clinical trials for the development of drugs and diagnostic tests) <ref type="bibr" target="#b27">35</ref> , however for digital health solutions, we found few studies employed strict individual randomized designs (Table <ref type="table" target="#tab_6">4</ref>; e.g., refs. <ref type="bibr" target="#b28">[36]</ref><ref type="bibr" target="#b29">[37]</ref></s><s xml:id="_ATtz3hE">7]<ref type="bibr" target="#b30">[38]</ref> ).</s><s xml:id="_xzrBxqM">One reason is that individual randomization is not always possible or appropriate as in the examples provided below.</s></p><p xml:id="_n9NPNpt"><s xml:id="_Y6xpeCp">Cluster-randomization trials (CRTs), by contrast, are better suited for digital solutions supporting group efforts (e.g.</s><s xml:id="_MmRCsCk">solutions supporting tumor board meetings <ref type="bibr" target="#b31">39</ref> ), and this approach has been increasingly adopted by public health researchers <ref type="bibr" target="#b32">[40]</ref><ref type="bibr" target="#b33">[41]</ref><ref type="bibr" target="#b34">[42]</ref> .</s><s xml:id="_PkR2QEn">CRTs are often used in situations when contamination may occur; for example, where individuals in the same cluster have been randomized to different intervention groups, or for logistic, feasibility or ethical reasons <ref type="bibr" target="#b35">43</ref> .</s><s xml:id="_JqWQJqW">Attractive features include: increased administrative efficiency; decreased risk of experimental contamination (e.g.</s><s xml:id="_JBrsYMJ">where control group individuals adopt the intervention) <ref type="bibr" target="#b35">43</ref> ; and, enhancement of subject compliance <ref type="bibr" target="#b36">44</ref> .</s><s xml:id="_Ws2GuNz">In addition, CRTs allow both direct and indirect effects of an intervention to be evaluated-a particular advantage when both effects are hypothesized to be important, e.g., in vaccine field trials <ref type="bibr" target="#b37">45</ref> .</s><s xml:id="_TNy5x4r">Disadvantages include: reduced statistical efficiency relative to IRTs <ref type="bibr" target="#b38">46</ref> ; overmatching; and, subsampling bias <ref type="bibr" target="#b39">47,</ref><ref type="bibr" target="#b40">48</ref> .</s><s xml:id="_q3sMk23">Analysis commonly employs multi-level modeling <ref type="bibr" target="#b41">49,</ref><ref type="bibr" target="#b42">50</ref> .</s></p><p xml:id="_UXPWJrX"><s xml:id="_Rme9BZc">Micro-randomization trials (MRTs) are helpful when researchers want to determine empirically the efficacy of a specific component (e.g., which component of an intervention should be delivered, and whether it had the intended effect) <ref type="bibr" target="#b24">32</ref> .</s><s xml:id="_a3TxvmB">MRT involves randomly assigning an intervention option at each time point that the component could be delivered (e.g., see examples in the ref. <ref type="bibr" target="#b43">51</ref></s><s xml:id="_erCtmSH">n p. 5 and ref. <ref type="bibr" target="#b44">52</ref> ) <ref type="bibr" target="#b43">51,</ref><ref type="bibr" target="#b44">52</ref> , and can be particularly powerful in the early stages of product development <ref type="bibr" target="#b43">51</ref> .</s><s xml:id="_FdnWteF">MRTs generate longitudinal data with repeated measures of participants' behaviors, context, and psychosocial factors, and can be analyzed by methods, such as multilevel models and generalized estimating equation <ref type="bibr" target="#b43">51,</ref><ref type="bibr" target="#b45">53,</ref><ref type="bibr" target="#b46">54</ref> .</s></p><p xml:id="_F85QVCX"><s xml:id="_YZ9qsdW">The most commonly used method for evaluating digital health solutions, however, is the pre-post design, as demonstrated by a previous systematic review <ref type="bibr" target="#b11">17</ref> and supported by our own searches (Table <ref type="table" target="#tab_6">4</ref>).</s><s xml:id="_qDAcTZP">A standard approach of pre-post design involves: prephase, which provides control data; "washout" period <ref type="bibr" target="#b47">55</ref> (i.e., with no interventions implemented with a time gap up to several months), to allow familiarization and to limit bias related to implementation <ref type="bibr" target="#b31">39,</ref><ref type="bibr" target="#b48">56</ref> ; post-phase to collect data on solution effectiveness.</s><s xml:id="_cWUkh6m">Existing studies are often undertaken at a single site (vs.</s><s xml:id="_hQPf63b">multi-site), which is typically more practical and affordable.</s><s xml:id="_6V6YXEr">Typically, this design requires a longer duration, making it difficult to evaluate continuous solution upgrades (i.e.</s><s xml:id="_CsgpvGW">new features and/or bug fixes), which are often observed in digital health products.</s><s xml:id="_DacAHGh">In addition, it is not optimal for testing medium-term or longer-term clinical outcomes, because it is difficult to determine independent effects when patients may appear in both pre-phase and postphase.</s><s xml:id="_ZamwETc">Data analysis generally employs methods, such as analysis of variance (ANOVA) and analysis of covariance (ANCOVA) or nonparametric tests (depending on the underlying distributions) <ref type="bibr" target="#b49">57</ref> .</s></p><p xml:id="_gsRxsX3"><s xml:id="_kgVeJKG">Relatively few multi-site studies have been conducted <ref type="bibr" target="#b11">17</ref> (we also listed some examples in Table <ref type="table" target="#tab_6">4</ref>), nevertheless, a variety of designs have been attempted in this context including: pre-post <ref type="bibr" target="#b50">58</ref> , cross-sectional with non-equivalent control <ref type="bibr" target="#b51">59</ref> , crosssectional with internal control <ref type="bibr" target="#b52">60</ref> , and randomized controlled trial <ref type="bibr" target="#b53">61</ref> .</s><s xml:id="_DRX8pYz">For multi-site RCTs, some sites are assigned as controls and the rest as the experimental condition.</s><s xml:id="_QcJkuka">For this approach, control and experimental sites should be matched along key characteristics (e.g., workflow, patient characteristics), which can be difficult to achieve.</s><s xml:id="_f5uQzk9">The main advantage is reduction in study duration.</s><s xml:id="_cQCyNn7">Disadvantages include: higher set-up efforts; increased cost; and, challenges to identify matched sites.</s><s xml:id="_NTpfFjc">Various tests are employed such as t-test, non-parametric tests, or other advanced techniques (depending on the underlying distributions) <ref type="bibr" target="#b54">62</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_JQNekSk">Retrospective studies</head><p xml:id="_gK8ATqr"><s xml:id="_WAN755Z">Retrospective studies can be employed to analyze pre-existing data, such as patient charts or electronic medical records.</s><s xml:id="_aVpuz3P">Types of retrospective studies include case series, cohort, or case-control studies.</s><s xml:id="_NbJebwv">They are typically quicker, cheaper, and easier <ref type="bibr" target="#b55">63</ref> than prospective studies because data are already collected, and are commonly used to generate hypotheses for further investigation by prospective studies.</s><s xml:id="_vUmNMcD">The disadvantages are, that they are subject to biases and confounding factors, such as patient information loss or distortion during data collection <ref type="bibr" target="#b56">64</ref> , risk factors</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_3QKxuf9">Increasing evidence level</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_qewkTjm">ProspecƟve RCT studies</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_qwGh27c">Longer-Ɵme to evidence generaƟon</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_4GrMGqN">Fast-evidence generaƟon</head><p xml:id="_d8rUfQS"><s xml:id="_NTbuU4C">ProspecƟve observaƟonal studies Survey and interviews (incl., usability tesƟng) Expert opinion / case example Methodological gap exists for faster and high-quality evidence generaƟon</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ZYTHdsF">InnovaƟve &amp; pragmaƟc approaches needed:</head><p xml:id="_jRztZGT"><s xml:id="_DDVa4kU">Is simulaƟon-based research an approach to bridge the gap?</s></p><p xml:id="_wysmF8h"><s xml:id="_DZnrEm5">RetrospecƟve observaƟonal studies Fig. <ref type="figure">1</ref> Existing approaches for health digital solution evaluation, current methodological gap and emerging innovative pragmatic approaches to fill such gap.</s><s xml:id="_Rs36BWx">Note, the position of each methodology is meant to be illustrative and reflecting general cases.</s></p><p xml:id="_7Vng9dT"><s xml:id="_zgWDskQ">present but not captured, normal growth or maturation influence, attrition (e.g.</s><s xml:id="_8u4n8E4">patients with unfavorable outcome(s) less likely to attend follow-up) <ref type="bibr" target="#b55">63,</ref><ref type="bibr" target="#b57">65</ref> , and selection bias due to non-random assignment of participants <ref type="bibr" target="#b57">65,</ref><ref type="bibr" target="#b58">66</ref> .</s><s xml:id="_kK5p8Be">Such biases threaten internal validity, therefore, retrospective studies are considered (particularly by the academic groups) inferior as compared to RCTs <ref type="bibr" target="#b55">[63]</ref><ref type="bibr" target="#b56">[64]</ref><ref type="bibr" target="#b57">[65]</ref><ref type="bibr" target="#b58">[66]</ref> .</s><s xml:id="_7rTWsGQ">It remains as an open question whether this is still the case for digital health solutions, particularly for the ones of lower-risk class.</s></p><p xml:id="_T6wqmAM"><s xml:id="_VBjnbHR">To date, few publications have evaluated digital solutions with retrospective data, likely due to limited use of digital solutions in clinical practice, and challenges for data access (e.g.</s><s xml:id="_hfScYMs">GDPR).</s><s xml:id="_3WaeU35">Nevertheless, one such study from India investigated concordance between the treatment recommendations of an artificial intelligence (AI) algorithm compared with actual tumor board recommendations <ref type="bibr" target="#b59">67</ref> (Table <ref type="table" target="#tab_6">4</ref>).</s><s xml:id="_8EW62BM">Strictly speaking this study was a hybrid of retrospective (treatment recommendations from Tumor Board 2014-2016) and prospective (treatment recommendations from AI algorithm in 2016).</s><s xml:id="_Uv5aWSV">A key limitation of the study was that breast cancer treatment knowledge was not constant for the two conditions, because of the evolving clinical practice standards.</s><s xml:id="_R2YPArf">Additional, prospective studies would be required to examine impacts on clinical outcomes, efficiency, and mental fatigue of clinicians.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Yz7p7rR">Systematic reviews</head><p xml:id="_7HhwRyK"><s xml:id="_RcBhjXR">Systematic reviews have a key role in evidence-based medicine and the development of clinical guidelines <ref type="bibr" target="#b60">[68]</ref><ref type="bibr" target="#b61">[69]</ref><ref type="bibr" target="#b62">[70]</ref> .</s><s xml:id="_BBaUswZ">Reviews on a specific solution can provide stronger evidence for its impacts, but require a sufficient number of individual evaluation studies.</s><s xml:id="_ka5hT7N">A possible limitation for such work in digital health is that included studies would need to be matched to the same mechanism of intervention, disease area, and measurable outcome.</s></p><p xml:id="_BJ8dA2s"><s xml:id="_TqvRyzu">Systematic reviews of prediction models are a new and evolving area and are increasingly undertaken to systematically identify, appraise, and summarize evidence on the performance of prediction models <ref type="bibr" target="#b63">[71]</ref><ref type="bibr" target="#b64">[72]</ref><ref type="bibr" target="#b65">[73]</ref> .</s><s xml:id="_DjvjDhz">Frameworks and tools exist to facilitate this including: prediction model risk of bias assessment tool (PROBAST), quality in prognosis studies (QUIPS), revised Cochrane randomized comparative design (ROB), risk of bias in nonrandomized studies of interventions (ROBINS-I).</s><s xml:id="_72qZzM3">Details provided in Table <ref type="table" target="#tab_4">2</ref>.</s></p><p xml:id="_Jr2EK2b"><s xml:id="_JuEqe6S">Economic evaluation Demonstration of positive economic benefits are critical for the majority of end-users to justify solution adoption.</s><s xml:id="_wYWtDnN">In addition, such data is important for other critical actors (e.g.</s><s xml:id="_P44QhSk">Payers, Government agencies, Professional Societies) to endorse the need for change.</s><s xml:id="_Aw3SrWF">The World Health Organization (WHO) guidelines provide a good overview of options for economic evaluation (Table <ref type="table" target="#tab_6">4</ref>.8 in WHO guideline 18 ) including: cost-effectiveness analysis, cost-benefit analysis, cost-consequence analysis, cost-minimization analysis, etc.</s><s xml:id="_7sSHNk7">However, for all of the aforementioned methods, tracking usage and performance data of users compared to non-users, is required.</s></p><p xml:id="_ARpSrEq"><s xml:id="_K3cBhx2">The critical evidence gaps for digital health solutions In general, approaches for evidence generation at early stages of product development deliver weaker evidence.</s><s xml:id="_xtWav34">Although, such efforts may be enough to support internal needs, and can convince "early adopters", they are insufficient to satisfy the "majority" of a solution's potential beneficiaries.</s><s xml:id="_5YSaMKv">These groups require, and expect, more robust, traditional evidence approaches.</s><s xml:id="_RYq7emQ">Currently, and in our opinion, there is a gap between quick, lowercost approaches applied at the early stages of product development and higher-cost approaches needed to convince the majority of stakeholders.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_QmPHUch">THE CHALLENGE OF THE TRADITIONAL APPROACH FOR DIGITAL HEALTH INNOVATORS</head><p xml:id="_y4rXJS6"><s xml:id="_WXJtCvp">It is our opinion that traditional methods to develop more robust evidence are incongruent with the agile approach taken in software development (e.g., mismatch between the length of RCTs and the typical development and update cycle of software).</s><s xml:id="_fhyjwZR">As such, traditional approaches present fundamental limitations for researchers to create evidence for digital health solutions.</s><s xml:id="_QKnXw96">In fact, evaluation of digital health solutions has been identified as requiring improvement, and has been cited as a major obstacle for wider adoption <ref type="bibr" target="#b66">[74]</ref><ref type="bibr" target="#b67">[75]</ref><ref type="bibr" target="#b68">[76]</ref> .</s><s xml:id="_FqDtg6y">The paradox at the heart of this problem is that, "without evidence healthcare providers would not adopt a solution; without solution adoption it is very difficult to generate evidence to convince healthcare providers".</s></p><p xml:id="_8xVNDWR"><s xml:id="_ZaKgHF8">Digital solution evaluation requires collective efforts from multiple parties, such as health authorities, healthcare providers (incl., academic medical centers), and manufacturers such as small and medium-sized enterprises (SMEs), multinational corporation (MNCs).</s><s xml:id="_V5VvUGK">Whilst they face shared difficulties with the current approaches for evidence generation (e.g.</s><s xml:id="_dmu7ww2">significant time and cost), they also have circumstance-specific challenges.</s></p><p xml:id="_2PDyAJp"><s xml:id="_tbvCPfF">SMEs-Limited resources to undertake clinical studies SMEs typically prioritize and allocate their research and development budget to product development.</s><s xml:id="_eJgAwZk">Anecdotal evidence suggests that close relationships between innovator and adopter are a critical driver of initial adoption decisions.</s><s xml:id="_KPMSH8y">Wider implementation requires robust evidence of benefit, yet this is difficult to prioritize given the many challenges for establishing new ventures.</s><s xml:id="_j85cCqD">In addition, well designed and executed studies require skilled researchers, often via collaboration with academia, adding further complexity.</s><s xml:id="_4T9mham">Moreover, it has been estimated that the timescale for submitting a research proposal and receiving ethical approval for a pilot or trial study can take as long as 3 years <ref type="bibr" target="#b12">19</ref> .</s><s xml:id="_9uwfka3">As demonstrated in a recent report <ref type="bibr" target="#b12">19</ref> , the biggest obstacle for providing evidence of effectiveness reported by companies, is the cost and timeframe for evaluation.</s></p><p xml:id="_VaeHK7J"><s xml:id="_UbcK7F2">MNCs-Out of date evidence not an investment priority Larger corporations have more resources to develop evidence but are equally limited by time.</s><s xml:id="_FFbrZef">For internal budget allocation, it can be difficult to provide rationale for investments into expensive and time-consuming clinical studies for early-stage solutions when such products are constantly evolving.</s><s xml:id="_79pqhwG">Given it typically takes 2-3 years to conduct a study, evidence published today may reflect a product that has been updated and refined multiple times.</s><s xml:id="_zRjgFkg">Furthermore, for many companies' investments in sales and manufacturing, for example, are more tangible with more predictable return on investment than those in clinical studies.</s></p><p xml:id="_bUnGpyR"><s xml:id="_taPBFS5">The same challenges (as SMEs) exist around navigating the complex infrastructure of the healthcare system, dealing with the cultural resistance to digital solutions, and identifying appropriate principle investigators for the evaluation studies.</s><s xml:id="_dMvScsY">Despite the longexisting collaborations between large health abd life science companies and principal investigators in, for example clinical trials for drug development, this group of researchers may not necessarily be willing to conduct studies to evaluate digital solutions, as they require different settings, capabilities and also deliver different scientific output-benefits on the operational level impacting cost and indirectly patient outcome versus a drug that can improve patient outcome directly.</s></p><p xml:id="_V365NHW"><s xml:id="_RSbrPSX">Academic institutions-focus on research output not widespread adoption A growing number of academic centers have created digital health research programs to develop and evaluate digital health solutions.</s><s xml:id="_u6rZWfZ">However, such research units generally favor traditional research methodologies because of increased likelihood of high-impact publication.</s><s xml:id="_nubd33t">As such, the timeliness of studies is largely immaterial, therefore, potentially valuable solutions may be delayed and/or are never implemented at scale.</s><s xml:id="_Wnd3pZB">Obtaining sufficient research funding can also be a challenge.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_vVFuZCx">EVOLVING PRAGMATIC APPROACHES FOR EVIDENCE GENERATION</head><p xml:id="_8d4re4p"><s xml:id="_CJJgnJd">In our opinion, large differences exist between the evidence required for initial adopters (e.g., surveys and interviews, case studies), and that required for the majority (prospective RCT studies).</s><s xml:id="_etefQZ7">Other research areas, such as drug development, have demonstrated that pragmatic approaches can be adopted to control cost at early stages (pragmatic clinical trials, basket of baskets, umbrella trials, etc. <ref type="bibr" target="#b69">[77]</ref><ref type="bibr" target="#b70">[78]</ref><ref type="bibr" target="#b71">[79]</ref> ).</s><s xml:id="_gaYR8ZF">The "gold standard" RCT remains but for later-stage final assessment.</s></p><p xml:id="_FuKh5hw"><s xml:id="_XQawdyA">The concept of "simulation" is not new and is the methodological foundation for human behavior experimental research (e.g.</s><s xml:id="_CM8fFEz">neuroscience and experimental psychology).</s><s xml:id="_Rndpr9X">The assumption is that people behave similar to real-life if key components of the scenarios are extracted and fidelity maintained.</s><s xml:id="_FvygdGm">Various approaches for simulation could be applied to evaluate digital solutions, such as, computational, system, and clinical simulation.</s></p><p xml:id="_CyCqVDW"><s xml:id="_rHhm8up">Computational simulation for software evaluation involves two steps: verification and validation <ref type="bibr" target="#b72">80</ref> .</s><s xml:id="_6X4xTeK">Verification checks if a system was built according to specification, and validation checks that a system meets user expectations.</s><s xml:id="_QphJ6d3">The most common application of computational has been for verification.</s><s xml:id="_jmJwNhJ">Typically, this involves simulated outcomes based on synthesized or real cases, before involving users/clinicians.</s><s xml:id="_UNMTTHB">Recent efforts have extended its use to non-regulated and on-market products (e.g., Google Alexa; Table <ref type="table" target="#tab_6">4</ref>).</s><s xml:id="_XbqbqpP">This approach is more applicable for products where the outputs can be evaluated for individual users, and not for clinical management tools where a group of users are targeted (e.g.</s><s xml:id="_J28vQRw">multidisciplinary tumor boards).</s></p><p xml:id="_T3cf8GA"><s xml:id="_XmEFyMH">System simulation adopts a system engineering view and methodology to model the effect of an intervention on a healthcare system (e.g.</s><s xml:id="_M7Tm6f8">multi-site hospital network) without disrupting the real health care setting <ref type="bibr" target="#b73">81</ref> .</s><s xml:id="_pGrrBXd">It has gained some traction (ASCO QCS Keynote topic by Joe Simone, literatures <ref type="bibr" target="#b74">82,</ref><ref type="bibr" target="#b75">83</ref> ), however, to date we are not aware of the use of system simulation to evaluate a digital health solution, perhaps because of the significant complexity to establish models that represent a healthcare system.</s></p><p xml:id="_Y2De732"><s xml:id="_ZcsdbHB">Clinical simulation was traditionally developed and used in training medical residents, and it was further developed as an approach to test systems and digital solutions with representative users doing representative tasks, in representative settings/ environments <ref type="bibr" target="#b76">84</ref> .</s><s xml:id="_8Nxhgvb">In our opinion, can be complementary to many of the traditional approaches reviewed above that require the use of a digital solution in real clinical practice, and could bridge the evidence needs between those of "early adopters" and the "majority".</s><s xml:id="_7XbCbHA">Clinical simulation provides a good balance between the strength of evidence (e.g., "near-live" clinical scenarios), whilst remaining cost-effective and timely for fast version updates (Fig. <ref type="figure">1</ref>).</s><s xml:id="_bHYQQna">Previous work demonstrated, the total cost for such a simulation was as little as 2750 USD, including set-up, subject and personnel cost <ref type="bibr" target="#b77">85</ref> .</s><s xml:id="_wBSbfjw">A recent cost-effective analysis suggested that introducing simulation into a product development lifecycle could lead to cost savings of 37-79% <ref type="bibr" target="#b78">86</ref> .</s><s xml:id="_8BVGM7Q">Other advantages include: scalability <ref type="bibr" target="#b12">19</ref> , flexibility in design of studies (e.g.</s><s xml:id="_jSzZTTc">different scenarios, various types of participants), feasibility in being implemented as remote and/or distributed <ref type="bibr" target="#b79">87</ref> , and ability to collect behavioral and/ or cognitive metrics.</s><s xml:id="_TEa5FnR">Sophisticated approaches and equipment can be employed, such as eye-tracker analysis or measurement of EEG, which would not be possible in real clinical practice.</s></p><p xml:id="_vdFBxGb"><s xml:id="_2hDMUZA">Furthermore, clinical simulation may also be helpful in facilitating patient engagement and/or Patient and Public Involvement and Engagement (PPIE), an initiative aiming to involving patients and/ or representatives from relevant public bodies in the research <ref type="bibr">88</ref> .</s></p><p xml:id="_vC5WhNQ"><s xml:id="_sTww4m2">Clinical simulation has been increasingly used in evaluating digital health solutions, including five studies in Table <ref type="table" target="#tab_6">4</ref>, and a further twenty studies from ITX-lab evaluating clinical information systems <ref type="bibr" target="#b80">89</ref> .</s><s xml:id="_GGFzeUA">For example, in one study <ref type="bibr" target="#b81">90</ref> primary care physicians interacted with videoclips of professional patient actors providing standardized responses to clinical scenarios and utilized a CDS tool of clinical prediction rules via an EMR system.</s><s xml:id="_RHVRQdj">In another recently published study <ref type="bibr" target="#b82">91</ref> , cognitive load and performance of physicians was evaluated for different conditions by randomly assigning participants to baseline EHR (control) or enhanced EHR (simulated environment with features such as automatic sorting and decision support instructions).</s><s xml:id="_64yXDHB">Moreover, a recent interview study of 10+ companies reported that they found this approach feasible for evidence generation for their own digital solution <ref type="bibr" target="#b12">19</ref> .</s></p><p xml:id="_xW4uXvS"><s xml:id="_nJX2P56">Several academic centers have established clinical simulation test environments, including: The School of Health Information Science (University of Victoria); The Department of Development and Planning (Aalborg University); The IT Experimentarium (ITX) lab (Danish Institute for Medical Simulation) <ref type="bibr" target="#b76">84</ref> ; and, The Institute of Global Health Innovation (IGHI) (Imperial Colleague London) <ref type="bibr">92</ref> .</s><s xml:id="_3BTuzDE">Indeed, researchers from IGHI have established a simulation test bed specifically to explore application to test digital health solutions.</s><s xml:id="_pcwPt8w">Initial work evaluated the impact of a digital solution on the conduction of cancer multidisciplinary team (MDT) meetings.</s><s xml:id="_z7BUSU2">56 healthcare professionals (e.g.</s><s xml:id="_CPSPwmd">pulmonologist, oncologists, radiologists, clinical nurse specialists, and thoracic surgeons), who were regular participants at lung cancer tumor boards, were recruited to take 10 simulated MDT sessions.</s><s xml:id="_CHr8pnc">High-fidelity mock patient cases were developed by the study team and clinical experts <ref type="bibr" target="#b83">93</ref> .</s><s xml:id="_Z8gdjyQ">Participants discussed up to 10 patient cases, using a standard UK approach to conduct MDTs (paper handout and PACS system) in the control condition, compared with the NAVIFY Tumor Board solution.</s><s xml:id="_zYQSVJF">A manuscript detailing the learnings and results from this pioneer work is under development.</s></p><p xml:id="_u8XSxSz"><s xml:id="_K5WCP7j">Whilst clinical simulation offers opportunities to prospectively test a digital solution quickly, safely and cost-effectively prior to implementation, there are a few limitations in its use.</s><s xml:id="_3h8Xksa">First, highfidelity is a prerequisite for generating valid and effective evidence.</s><s xml:id="_rBXYcG6">Therefore, researchers should take efforts to create scenarios representing real clinical practice, recruit the most representative end-users as participants, and provide comprehensive trainings of the digital solutions to the participants before their simulation sessions.</s><s xml:id="_hvuGpZN">Second, while the regulatory space evolves fast, we think clinical simulation results itself alone probably are not adequate for approval application from Health authorities, particularly for higher-risk group of digital solutions that would need to be approved as SaMD.</s><s xml:id="_vNZFgcC">Nevertheless, in these cases, clinical simulations can help to provide initial insights for product development, reduce safety risk for patients, and guide the design of large-scale real clinical studies.</s><s xml:id="_Q6bddXc">Third, for digital solutions that are already adopted in clinical practice, leveraging real-word data (RWD) is probably more suitable.</s><s xml:id="_b9v6t2E">RWD studies could be systematically employed to undertake near real-time evaluation during pilot implementation and post-market monitoring.</s><s xml:id="_uZ622u8">Indeed, studies utilizing real-world data (RWD) have been encouraged to support regulatory decision making (e.g.</s><s xml:id="_wyvDfgz">The 21st Century Cures Act; Table <ref type="table" target="#tab_5">3</ref>); have been used for clinical evidence generation (e.g.</s><s xml:id="_b8GHfh8">diagnostic and treatment patterns) <ref type="bibr" target="#b84">[94]</ref><ref type="bibr" target="#b85">[95]</ref><ref type="bibr" target="#b86">[96]</ref> ; and can demonstrate solution utility (e.g.</s><s xml:id="_dH2fgpG">meta-data associated with solution features and functionalities).</s></p><p xml:id="_fdM4wCt"><s xml:id="_dAGTryQ">Finally, we believe clinical simulation can be employed in combination with traditional study designs, e.g., individualrandomization, cluster-level randomization, and microrandomization to examine different types of digital solutions.</s></p><p xml:id="_TeP6KAQ"><s xml:id="_59C9sSB">For example, clinical simulation-based study with microrandomization design can be a powerful and pragmatic to evaluate the digital solutions with multiple components at early stage of the product development.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_5cX59PV">CONCLUSION</head><p xml:id="_3pCy4k4"><s xml:id="_Q9YfXSr">Innovators face significant challenges to overcome the "no evidence, no implementation-no implementation, no evidence" paradox in digital health.</s><s xml:id="_nb4zMeJ">We believe that innovative approaches, such as simulation-based research, can enable the generation of higher-quality, lower-cost, and more timely evidence.</s><s xml:id="_huB2Eqj">By considering such methods, end-users will encourage developers to undertake research activities, rather than be intimidated by the complexity, cost, and duration of traditional approaches.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p xml:id="_ETuYQsa"><s xml:id="_5yrcXJ7">Selected guidance and discussion documents relevant to digital health solutions (not exhaustive).</s></p></div></figDesc><table><row><cell>Main activities of releasing</cell><cell>organization</cell><cell>PCHA is a membership-based</cell><cell>Healthcare Information and</cell><cell>Management Systems Society</cell><cell>(HIMSS) Innovation Company. HIMSS</cell><cell>is a global advisor and thought</cell><cell>leader supporting the</cell><cell>transformation of health through the</cell><cell>application of information and</cell><cell>technology.</cell><cell>The FDA is responsible for protecting</cell><cell>and promoting public health</cell><cell>throught the control and</cell><cell>supervision, amongst other things,</cell><cell>e.g., medical devices.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>International Public Health</cell><cell></cell><cell></cell><cell>Executive branch of the</cell><cell>European Union</cell></row><row><cell>Organization responsible</cell><cell></cell><cell>Personalized Connected</cell><cell>Healthcare Alliance (PCHA)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Food &amp; Drug</cell><cell>Administration (FDA)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>World Health</cell><cell>Organization (WHO)</cell><cell></cell><cell>European Commission</cell></row><row><cell>Date first</cell><cell>published</cell><cell>2010</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>2016</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>2016</cell><cell></cell><cell></cell><cell>2016</cell></row><row><cell>Applicable areas within</cell><cell>digital health</cell><cell>Connected devices and</cell><cell>mobile applications (particular</cell><cell>emphasis on interoperability</cell><cell>and data standards)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>All digital health solutions</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>All digital health solutions</cell><cell></cell><cell></cell><cell>Healthare software</cell></row><row><cell>Document descriptions</cell><cell></cell><cell>Defining a framework of underlying</cell><cell>standards and criteria that are</cell><cell>required to ensure the interoperability</cell><cell>of components used for applications</cell><cell>monitoring personal health and</cell><cell>wellness.</cell><cell></cell><cell></cell><cell></cell><cell>Providing a general framework to</cell><cell>evaluate medical devices in both the</cell><cell>benefits (7 dimensions, such as types,</cell><cell>magnitude, likelihood of patients</cell><cell>experiencing one or more benefits,</cell><cell>etc.) and risks (7 dimensions, such as</cell><cell>risk severity, likelihood of risk, false-</cell><cell>positive or false-negative results,</cell><cell>patient tolerance of risk, etc.)</cell><cell>Provides a general framework for the</cell><cell>evaluation and validation of digital</cell><cell>solutions along its product mature</cell><cell>life-cycle</cell><cell>Describing when software does and</cell><cell>does not qualify as a medical or</cell><cell>in vitro diagnostic device</cell></row><row><cell>Document title</cell><cell></cell><cell>Continua Design Guidelines</cell><cell>(CDG) 97</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>FDA's benefit-risk framework for</cell><cell>medical devices 11</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>WHO monitoring and evaluating</cell><cell>digital health interventions 18</cell><cell></cell><cell>Guidelines on the Qualification and</cell><cell>Classification of Stand Alone</cell><cell>Software Used in Healthcare within</cell><cell>the Regulatory Framework of</cell><cell>Medical Devices (MEDDEV 2.1/6) 98</cell><cell>IMDRF SaMD Key Definitions (N10),</cell><cell>IMDRF SaMD Risk Categorization</cell><cell>Framework (N12), IMDRF SaMD</cell><cell>Quality Management Systems</cell><cell>(N23), and IMDRF SaMD Clinical</cell><cell>Evaluation (N41)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 2 .</head><label>2</label><figDesc><div><p xml:id="_Mu8ShZn"><s xml:id="_Dru9utb">Selected academic recommendations relevant to undertaking evidence generation studies for digital health solutions (not exhaustive).</s></p></div></figDesc><table><row><cell>Tool/framework</cell><cell>Document descriptions</cell><cell cols="2">Applicable areas within digital health Date first</cell></row><row><cell></cell><cell></cell><cell></cell><cell>published</cell></row><row><cell cols="2">Quality in prognosis studies (QUIPS) 101 6 factors to consider when evaluating validity and</cell><cell>Prognosis models (incl.,</cell><cell>2006</cell></row><row><cell></cell><cell>bias in studies of prognostic factors: participation,</cell><cell>individualized predictive model)</cell><cell></cell></row><row><cell></cell><cell>attrition, prognostic factor measurement,</cell><cell></cell><cell></cell></row><row><cell></cell><cell>confounding measurement and account, outcome</cell><cell></cell><cell></cell></row><row><cell></cell><cell>measurement, and analysis and reporting</cell><cell></cell><cell></cell></row><row><cell>The Cochrane risk-of-bias tool for</cell><cell>Set of domains of bias to guide the evaluation</cell><cell>Randomized studies (suitable for</cell><cell>2008 (updated</cell></row><row><cell>randomized trials (RoB2) 102</cell><cell>about features of a trial that are relevant to risk of</cell><cell>individually randomized, parallel-</cell><cell>in 2011)</cell></row><row><cell></cell><cell>bias based on answers to the signaling questions</cell><cell>group trials)</cell><cell></cell></row><row><cell>The risk of bias in nonrandomized</cell><cell>Tool to assess risk of bias in non-randomized</cell><cell>Non-randomized studies</cell><cell>2016</cell></row><row><cell>studies of interventions (ROBINS-I) 103</cell><cell>studies over 7 domains (e.g., missing data,</cell><cell></cell><cell></cell></row><row><cell></cell><cell>participant selection, etc.)</cell><cell></cell><cell></cell></row><row><cell>PROBAST: A Tool to Assess the Risk of</cell><cell>Tool to assess the risk of bias and applicability of</cell><cell>Predictive models (incl., CDS</cell><cell>2019</cell></row><row><cell>Bias and Applicability of Prediction</cell><cell>prediction model studies (20 questions). Informed</cell><cell>algorithms)</cell><cell></cell></row><row><cell>Model Studies 104</cell><cell>by a Delphi procedure involving 38 experts and</cell><cell></cell><cell></cell></row><row><cell></cell><cell>refined through piloting. It is not suitable for</cell><cell></cell><cell></cell></row><row><cell></cell><cell>comparative studies.</cell><cell></cell><cell></cell></row><row><cell cols="3">The digital health scorecard All digital health solutions</cell><cell>2019</cell></row></table><note xml:id="_5RxWcsq"><p><ref type="bibr" target="#b1">2</ref> </p><p><s xml:id="_BHCmbFE">Academic developed framework that proposes validation should include three aspects: (1) technical validation (e.g., how accurately does the solution measure what it claims?), (</s><s xml:id="_zxQmQzH"> clinical validation (e.g., does the solution have any support for improving condition-specific outcomes?),</s><s xml:id="_ErK3CyW">(3) system validation (e.g., does the solution integrate into patients' lives, provider workflows, and healthcare systems).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 3 .</head><label>3</label><figDesc><div><p xml:id="_XsYVprY"><s xml:id="_d4bXHbh">Selected regulations and standards relevant to digital health solutions (not exhaustive).</s></p></div></figDesc><table><row><cell>Main activities of releasing organization</cell><cell></cell><cell>International Electrotechnical</cell><cell>Commission</cell><cell></cell><cell></cell><cell></cell><cell>The International Organization for</cell><cell>Standardization is an international</cell><cell>standard-setting body composed of</cell><cell>representatives from various national</cell><cell>standards organizations. ISO (35.240.80)</cell><cell>pertains to IT Applications in Health Care</cell><cell>Technology</cell><cell>As above</cell><cell></cell><cell></cell><cell></cell><cell>As above</cell><cell></cell><cell></cell><cell></cell><cell>NA</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Executive branch of the European Union</cell><cell></cell><cell></cell><cell></cell><cell>As above</cell><cell>As above</cell></row><row><cell>Organization responsible</cell><cell></cell><cell>International Standards</cell><cell>Organization (ISO)</cell><cell></cell><cell></cell><cell></cell><cell>International Standards</cell><cell>Organization (ISO)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>International Standards</cell><cell>Organization (ISO)</cell><cell></cell><cell></cell><cell>International Standards</cell><cell>Organization (ISO)</cell><cell></cell><cell></cell><cell>Passed by Congress and</cell><cell>signed into law by the</cell><cell>President</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>European Commission</cell><cell></cell><cell></cell><cell></cell><cell>International Standards</cell><cell>Organization (ISO)</cell><cell>International Standards</cell><cell>Organization (ISO)</cell></row><row><cell>Date first</cell><cell>published</cell><cell>2006</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>2011</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>2014</cell><cell></cell><cell></cell><cell></cell><cell>2015</cell><cell></cell><cell></cell><cell></cell><cell>2016</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>2017</cell><cell></cell><cell></cell><cell></cell><cell>2017</cell><cell>Upcoming</cell></row><row><cell>Applicable areas</cell><cell>within digital health</cell><cell>Medical device</cell><cell>software</cell><cell></cell><cell></cell><cell></cell><cell>IT applications in</cell><cell>healthcare</cell><cell>technology</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>IT applications in</cell><cell>healthcare</cell><cell>technology</cell><cell></cell><cell>IT applications in</cell><cell>healthcare</cell><cell>technology</cell><cell></cell><cell>All digital health</cell><cell>solutions</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Software as a</cell><cell>Medical Device</cell><cell>(SaMD) (Rule 17)</cell><cell></cell><cell>IT applications in</cell><cell>healthcare</cell><cell>technology</cell><cell>IT applications in</cell><cell>healthcare</cell><cell>technology</cell></row><row><cell>Document descriptions</cell><cell></cell><cell>Providing life cycle requirements for the</cell><cell>development of medical software and</cell><cell>software within medical devices. It is</cell><cell>harmonized by the European Union (EU) and</cell><cell>the United States (US)</cell><cell>Defines the set of requirements for the</cell><cell>architecture of a system that processes,</cell><cell>manages and communicates electronic</cell><cell>health record (EHR) information: an EHR</cell><cell>architecture</cell><cell></cell><cell></cell><cell>Provides guidance for organizations charged</cell><cell>with creating or applying maps to meet their</cell><cell>business needs.</cell><cell></cell><cell>Provides a reference list of functions that</cell><cell>may be present in an Electronic Health</cell><cell>Record System (EHR-S)</cell><cell></cell><cell>Providing broad scope related to health,</cell><cell>with one part covering expedited product</cell><cell>development programs, including the</cell><cell>regenerative medicine advanced therapy,</cell><cell>and the breakthrough devices program</cell><cell>(designed to speed the review of certain</cell><cell>innovative medical devices)</cell><cell>The entirety of the Regulation is applicable</cell><cell>for SaMD products, however, classification</cell><cell>Rule 17 specifically applies to software</cell><cell>products</cell><cell>Contains principles and requirements for</cell><cell>privacy protection using pseudonymization</cell><cell>services for the protection of personal health</cell><cell>information.</cell><cell>Under development</cell></row><row><cell>Document title</cell><cell></cell><cell>IEC 62304: Medical device software-</cell><cell>software life cycle processes 105</cell><cell></cell><cell></cell><cell></cell><cell>ISO 18308:2011</cell><cell>Health informatics-Requirements for</cell><cell>an electronic health record</cell><cell>architecture 106</cell><cell></cell><cell></cell><cell></cell><cell>ISO/TR 12300:2014</cell><cell>Health informatics-Principles of</cell><cell>mapping between terminological</cell><cell>systems 107</cell><cell>ISO/HL7 10781:2015 [HL7]</cell><cell>Health Informatics-HL7 Electronic</cell><cell>Health Records-System Functional</cell><cell>Model, Release 2 (EHR FM) 108</cell><cell>US 21st Century Cures Act 109</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Medical Device Regulation (MDR)-</cell><cell>Regulation (EU) 2017/745 110</cell><cell></cell><cell></cell><cell>ISO 25237:2017</cell><cell>Health informatics-</cell><cell>Pseudonymization 111</cell><cell>ISO/IEC CD 23053</cell><cell>Framework for Artificial Intelligence</cell><cell>(AI) Systems Using Machine Learning</cell><cell>(ML) 112</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 4 .</head><label>4</label><figDesc><div><p xml:id="_jPhYRZ8"><s xml:id="_TxX5gCV">Recent studies utilizing various methodologies in evaluating digital health solutions (not exhaustive).</s></p></div></figDesc><table><row><cell>Study length</cell><cell></cell><cell></cell><cell>2 years (2014-2016)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>4 years (2007-2011)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>3 years</cell><cell></cell><cell></cell><cell></cell><cell>2 years (2016-2017)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>End-2-end study length not found in</cell><cell>the paper</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>NA</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>2015-2016</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>12 weeks for the conduction stage;</cell><cell>end-to-end study length not</cell><cell>reported</cell></row><row><cell>Number of sites</cell><cell>involved during</cell><cell>evaluation</cell><cell>Single</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Single</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Multi</cell><cell></cell><cell></cell><cell></cell><cell>Multi</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Multi</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Multi</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Multi</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Multi</cell><cell></cell><cell></cell></row><row><cell>Sample size</cell><cell></cell><cell></cell><cell>120 patients</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>766 patients, with 441 in the</cell><cell>intervention cofthagenondition and</cell><cell>325 in the control condition</cell><cell>(usual care)</cell><cell></cell><cell></cell><cell>338 patients on Text messaging (TM)</cell><cell>condition, and 338 on non-TM</cell><cell></cell><cell></cell><cell>Implementation site: 767 patients in</cell><cell>pre vs. 439 in post; Control site: 1016</cell><cell>in pre-and 422 in post</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>13 patients with type 2 diabetes in</cell><cell>the intervention group vs. 13 in</cell><cell>control</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>120 children to be recruited</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Immediate telehealth availability (n</cell><cell>= 925 patients in service areas of 13</cell><cell>primary care clinics offering</cell><cell>telehealth) vs. availability 1 year later</cell><cell>(n = 745 patients in 12 clinics)</cell><cell></cell><cell>109 participants (12 sites) in total,</cell><cell>within 80 participants (7 sites) in the</cell><cell>DMO condition, and 29 participants</cell><cell>(5 sites) in usual care</cell></row><row><cell>Design/method details</cell><cell></cell><cell></cell><cell>A web-mediated follow-up algorithm</cell><cell>based on self-reported symptoms</cell><cell>improved OS (18 vs. 12 months in the</cell><cell>experimental and control arm,</cell><cell>respectively) due to early relapse</cell><cell>detection and better performance</cell><cell>status at relapse</cell><cell>Patients randomly assigned to</cell><cell>routine outpatient chemotherapy for</cell><cell>advanced solid tumors with patient-</cell><cell>reported outcomes vs. usual care</cell><cell>with symptom monitoring at the</cell><cell>discretion of clinicians</cell><cell>Randomized trial of text messaging</cell><cell>to reduce early discontinuation of</cell><cell>aromatase inhibitor therapy in</cell><cell>women with breast cancer</cell><cell>Clinical outcome data were collected</cell><cell>from adults with AKI on emergency</cell><cell>admission before and after</cell><cell>deployment at the intervention site</cell><cell>and another not receiving the</cell><cell>intervention (multi-site, pre-&amp; post</cell><cell>intervention design)</cell><cell>Patients with type 2 diabetes were</cell><cell>recruited from three community</cell><cell>physician practices and evenly</cell><cell>randomized between intervention</cell><cell>(cell phone-based software designed</cell><cell>by endocrinologists, etc.) and control</cell><cell>(One Touch Ultra™ BG meters)</cell><cell>Protocol proposal for employing a</cell><cell>stepped wedge design in which the</cell><cell>WebMAP mobile intervention is</cell><cell>sequentially implemented in</cell><cell>8 specialty pain clinics following a</cell><cell>usual care period</cell><cell>A Cluster-Randomized Program</cell><cell>Evaluation in the Veterans Health</cell><cell>Administration to evaluate the</cell><cell>impact of availability of Telehealth</cell><cell>Programs on Documented HIV Viral</cell><cell>Suppression</cell><cell>Participants with elevated systolic BP</cell><cell>(SBP ≥ 140 mm Hg) and HbA1c (≥7%)</cell><cell>failing antihypertensive (≥2</cell><cell>medications) and oral diabetes</cell><cell>therapy were enrolled in this three-</cell></row><row><cell>Digital solution</cell><cell></cell><cell></cell><cell>Web-mediated follow-up</cell><cell>algorithm 113</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Patient-reported outcomes</cell><cell>collected via tablet 36</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Text messaging 37</cell><cell></cell><cell></cell><cell></cell><cell>Digitally enabled care pathway</cell><cell>for acute kidney injury</cell><cell>management 114</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>WellDoc® mobile diabetes</cell><cell>management tool 38</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Internet-delivered pain self-</cell><cell>management program</cell><cell>(WebMAP) 115</cell><cell></cell><cell></cell><cell></cell><cell>Telehealth programs 41</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Digital medicine offering (DMO;</cell><cell>medication taken with ingestible</cell><cell>sensor) measuring medication</cell><cell>ingestion adherence, physical</cell><cell>activity, etc. 116</cell></row><row><cell>Evaluation approach</cell><cell></cell><cell></cell><cell>Prospective: Randamized</cell><cell>comparative design</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Prospective: custer</cell><cell>randomized design</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_pxjJMCA"><s xml:id="_FnwTz8R">npj Digital Medicine (2020) 110 Scripps Research Translational Institute</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1"><p xml:id="_SFrNvAf"><s xml:id="_uSQvJsC">Scripps Research Translational Institutenpj Digital Medicine (2020) 110</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head xml:id="_uw6skc3">ACKNOWLEDGEMENTS</head><p xml:id="_kvVmSH2"><s xml:id="_2ETKZKA">We acknowledge <rs type="person">Nate Carrington</rs> from <rs type="affiliation">Roche</rs> for his valuable input on the regulations related to digital health solutions in the US and European markets.</s></p></div>
			</div>
			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_YbPsHcm">DATA AVAILABILITY</head><p xml:id="_Sfp88Yg"><s xml:id="_qxUK2Bb">All data supporting the findings of this study are available within the paper.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_uVnpHDs">AUTHOR CONTRIBUTIONS</head><p xml:id="_vD547Ef"><s xml:id="_2Zeqzdz">All authors (C.H.G., H.A., S.G., G.F., C.G., M.P.) contributed to the conception of the work, analysis and interpretation of the data, drafting the work and revising critically, final approval of the completed version, and accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_z3NazGX">COMPETING INTERESTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_8xQrn2e">ADDITIONAL INFORMATION</head><p xml:id="_ecAjhJ7"><s xml:id="_cJ5TaJc">Correspondence and requests for materials should be addressed to M.P.</s></p><p xml:id="_ZHVcpeM"><s xml:id="_7CMBwBu">Reprints and permission information is available at <ref type="url" target="http://www.nature.com/reprints">http://www.nature.com/  reprints</ref> Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_F2zZvyf">Digital health care-the convergence of health care and the Internet</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Frank</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_aj8y3gM">J. Ambul. Care Manag</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="8" to="17" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Frank, S. R. Digital health care-the convergence of health care and the Internet. J. Ambul. Care Manag. 23, 8-17 (2000).</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_35HusJn">Digital health: a path to validation</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Mathews</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ywNrrQF">NPJ digital medicine</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1" to="9" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mathews, S. C. et al. Digital health: a path to validation. NPJ digital medicine 2, 1-9 (2019).</note>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<author>
			<persName><surname>Iqvia</surname></persName>
		</author>
		<ptr target="https://www.iqvia.com/newsroom/2017/11/impact-of-digital-health-grows-as-innovation-evidence-and-adoption-of-mobile-health-apps-accelerate/" />
		<title level="m" xml:id="_eQQVCQG">IQVIA Institute for Human Data Science Study: Impact of Digital Health Grows as Innovation, Evidence and Adoption of Mobile Health Apps Accelerate</title>
		<imprint>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">IQVIA. IQVIA Institute for Human Data Science Study: Impact of Digital Health Grows as Innovation, Evidence and Adoption of Mobile Health Apps Accelerate. https://www.iqvia.com/newsroom/2017/11/impact-of-digital-health-grows-as- innovation-evidence-and-adoption-of-mobile-health-apps-accelerate/ (2017).</note>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Rogers</surname></persName>
		</author>
		<idno type="DOI">10.4324/9780203932445-8</idno>
		<title level="m" xml:id="_ppqAkPq">Diffusion of innovations</title>
		<imprint>
			<publisher>Simon and Schuster</publisher>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rogers, E. M. Diffusion of innovations. Simon and Schuster (2010).</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_MwdN6SV">The physical-digital divide: exploring the social gap between digital natives and physical natives</title>
		<author>
			<persName><forename type="first">C</forename><surname>Ball</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Q6nUVX5">J. Appl. Gerontol</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="1167" to="1184" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ball, C. et al. The physical-digital divide: exploring the social gap between digital natives and physical natives. J. Appl. Gerontol. 38, 1167-1184 (2019).</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_BwwR5rQ">Aging in the digital age: conceptualizing technology adoption and digital inequalities</title>
		<author>
			<persName><forename type="first">J</forename><surname>Francis</surname></persName>
		</author>
		<idno type="DOI">10.1007/978-981-13-3693-5_3</idno>
	</analytic>
	<monogr>
		<title level="m" xml:id="_UkzE8Rf">Ageing and digital technology</title>
		<meeting><address><addrLine>Singapore</addrLine></address></meeting>
		<imprint>
			<publisher>Springer</publisher>
			<date type="published" when="2019">2019</date>
			<biblScope unit="page" from="35" to="49" />
		</imprint>
	</monogr>
	<note type="raw_reference">Francis, J. et al. Aging in the digital age: conceptualizing technology adoption and digital inequalities. In Ageing and digital technology, 35-49 (Springer, Singapore, 2019).</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_DDnj7Fg">What it takes to successfully implement technology for aging in place: focus groups with stakeholders</title>
		<author>
			<persName><forename type="first">S</forename><surname>Peek</surname></persName>
		</author>
		<idno type="DOI">10.2196/jmir.5253</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Usu4drq">J. Med. Internet Res</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">98</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Peek, S. et al. What it takes to successfully implement technology for aging in place: focus groups with stakeholders. J. Med. Internet Res. 18, e98 (2016).</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_XS8UFGB">Bridging the digital divide in older adults: a study from an initiative to inform older adults about new technologies</title>
		<author>
			<persName><forename type="first">Y. -H</forename><surname>Wu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_szzdsDn">Clin. Interv. Aging</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="193" to="201" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wu, Y. -H. et al. Bridging the digital divide in older adults: a study from an initiative to inform older adults about new technologies. Clin. Interv. Aging 10, 193-201 (2015).</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_kfWhbAA">FDA regulation of mobile medical apps</title>
		<author>
			<persName><surname>Shuren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Q5DG2u9">JAMA</title>
		<imprint>
			<biblScope unit="volume">320</biblScope>
			<biblScope unit="page" from="337" to="338" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shuren et al. FDA regulation of mobile medical apps. JAMA, 320, 337-338 (2018).</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_mayeyAm">Introducing evidence-based medicine to plastic and reconstructive surgery</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Chung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZbGnj2Y">Plast. Reconstr. Surg</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page">1385</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chung, K. C. et al. Introducing evidence-based medicine to plastic and recon- structive surgery. Plast. Reconstr. Surg. 123, 1385 (2009).</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_89kWTsZ">Observational studies: cohort and case-control studies</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Song</surname></persName>
		</author>
		<idno type="DOI">10.1097/prs.0b013e3181f44abc</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_QEt7FzK">Plast. Reconstr. Surg</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page">2234</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Song, J. W. et al. Observational studies: cohort and case-control studies. Plast. Reconstr. Surg. 126, 2234 (2010).</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_pmqVMfB">A systematic review of clinical decision support systems for clinical oncology practice</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Pawloski</surname></persName>
		</author>
		<idno type="DOI">10.6004/jnccn.2018.7104</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5fAmTZa">J. Natl. Compr. Canc. Netw</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="331" to="338" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pawloski, P. A. et al. A systematic review of clinical decision support systems for clinical oncology practice. J. Natl. Compr. Canc. Netw. 17, 331-338 (2019).</note>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<author>
			<persName><forename type="first">S</forename><surname>Ghafur</surname></persName>
		</author>
		<title level="m" xml:id="_ZyMm4RT">A simulation test bed: the solution to the obstacles of evaluating the effectiveness of digital health interventions</title>
		<imprint/>
	</monogr>
	<note>in preparation</note>
	<note type="raw_reference">Ghafur, S. et al. A simulation test bed: the solution to the obstacles of evaluating the effectiveness of digital health interventions (in preparation).</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_MSTn2DH">Web-based survey on the effect of digital storytelling on empowering women to seek help for urogenital atrophy</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Cumming</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_YxuQ8sp">Menopause Int</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="51" to="55" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cumming, G. P. et al. Web-based survey on the effect of digital storytelling on empowering women to seek help for urogenital atrophy. Menopause Int. 16, 51-55 (2010).</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_mX585QH">Health-care disparities stemming from sexual orientation of Italian patients with Multiple Sclerosis: a cross-sectional web-based study</title>
		<author>
			<persName><forename type="first">L</forename><surname>Lavorgna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2BNKa5F">Mult. Scler. Relat. Disord</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="28" to="32" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lavorgna, L. et al. Health-care disparities stemming from sexual orientation of Italian patients with Multiple Sclerosis: a cross-sectional web-based study. Mult. Scler. Relat. Disord. 13, 28-32 (2017).</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_RaWhGUb">Attitudes towards digital treatment for depression: a European stakeholder survey</title>
		<author>
			<persName><forename type="first">N</forename><surname>Topooco</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.invent.2017.01.001</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6c8tvp2">Internet Interv</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="1" to="9" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Topooco, N. et al. Attitudes towards digital treatment for depression: a Eur- opean stakeholder survey. Internet Interv. 8, 1-9 (2017).</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_4waX5Jm">Hierarchy of evidence: a framework for ranking evidence evaluating healthcare interventions</title>
		<author>
			<persName><forename type="first">D</forename><surname>Evans</surname></persName>
		</author>
		<idno type="DOI">10.1046/j.1365-2702.2003.00662.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zsc5cHz">J. Clin. Nurs</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="77" to="84" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Evans, D. Hierarchy of evidence: a framework for ranking evidence evaluating healthcare interventions. J. Clin. Nurs. 12, 77-84 (2003).</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_mmpdCgV">Development and usability analysis of a multimedia eConsent solution</title>
		<author>
			<persName><forename type="first">H</forename><surname>Schneiderheinze</surname></persName>
		</author>
		<idno type="DOI">10.3233/shti190841</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_QPTxGM4">Stud. Health Technol. Inform. In GMDS</title>
		<imprint>
			<biblScope unit="page" from="297" to="303" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Schneiderheinze, H. et al. Development and usability analysis of a multimedia eConsent solution. Stud. Health Technol. Inform. In GMDS, 297-303 (2019).</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_q5sVpna">How inclusive, user-centered design research can improve psychological therapies for psychosis: development of SlowMo</title>
		<author>
			<persName><forename type="first">A</forename><surname>Hardy</surname></persName>
		</author>
		<idno type="DOI">10.2196/11222</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TFmXnvw">JMIR Ment. Health</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">11222</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hardy, A. et al. How inclusive, user-centered design research can improve psychological therapies for psychosis: development of SlowMo. JMIR Ment. Health 5, e11222 (2018).</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_Vgh5umP">Methods of usability testing in the development of eHealth applications: a scoping review</title>
		<author>
			<persName><forename type="first">I</forename><surname>Maramba</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ijmedinf.2019.03.018</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_b6pWyUh">Int. J. Med. Inform</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="95" to="104" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Maramba, I. et al. Methods of usability testing in the development of eHealth applications: a scoping review. Int. J. Med. Inform. 126, 95-104 (2019).</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_7gkhXbS">Comparative usability evaluation</title>
		<author>
			<persName><surname>Molich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3s59gey">Behav. Inf. Technol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="65" to="74" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Molich, et al. Comparative usability evaluation. Behav. Inf. Technol. 23, 65-74 (2004).</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_DNbXF6y">An exploratory usability evaluation of Colorado State University Libraries&apos; digital collections and the Western Waters Digital Library Web sites</title>
		<author>
			<persName><forename type="first">Paschal</forename><surname>Zimmerman</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.acalib.2009.03.011</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ufUe5Zk">J. Acad. Librarianship</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="227" to="240" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zimmerman &amp; Paschal. An exploratory usability evaluation of Colorado State University Libraries&apos; digital collections and the Western Waters Digital Library Web sites. J. Acad. Librarianship. 35, 227-240 (2009).</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_MExxYS8">Beyond the five-user assumption: benefits of increased sample sizes in usability testing</title>
		<author>
			<persName><forename type="first">L</forename><surname>Faulkner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pvkazfU">Behav. Res. Methods</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="379" to="383" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Faulkner, L. Beyond the five-user assumption: benefits of increased sample sizes in usability testing. Behav. Res. Methods 35, 379-383 (2003).</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_rR2uYvg">Systematic reviews in health care: assessing the quality of controlled clinical trials</title>
		<author>
			<persName><forename type="first">P</forename><surname>Jüni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RTcPaFK">BMJ</title>
		<imprint>
			<biblScope unit="volume">323</biblScope>
			<biblScope unit="page" from="42" to="46" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jüni, P. et al. Systematic reviews in health care: assessing the quality of con- trolled clinical trials. BMJ 323, 42-46 (2001).</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_XT4Bney">Mobile health technology evaluation: the mHealth evidence workshop</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kumar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_sQUzGB6">Am. J. Prev. Med</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="228" to="236" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kumar, S. et al. Mobile health technology evaluation: the mHealth evidence workshop. Am. J. Prev. Med. 45, 228-236 (2013).</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_CANAHAz">Digital health: Smartphone-based monitoring of multiple sclerosis using Floodlight</title>
		<author>
			<persName><surname>Baker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RNcG7Hv">Nature</title>
		<imprint>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Baker, et al. Digital health: Smartphone-based monitoring of multiple sclerosis using Floodlight. Nature (2019).</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_BYw9wWh">Whole-slide image focus quality: automatic assessment and impact on AI cancer detection</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kohlberger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_MGJcCZF">J. Pathol. Inform</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kohlberger, T. et al. Whole-slide image focus quality: automatic assessment and impact on AI cancer detection. J. Pathol. Inform. 10 (2019).</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_XUA8Vf4">Epidemiology and reporting of randomised trials published in PubMed journals</title>
		<author>
			<persName><forename type="first">A.-W</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(05)71879-1</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JBNHxZh">Lancet</title>
		<imprint>
			<biblScope unit="volume">365</biblScope>
			<biblScope unit="page" from="1159" to="1162" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chan, A.-W. &amp; Altman, D. G. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet 365, 1159-1162 (2005).</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_PvzFVM8">Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial</title>
		<author>
			<persName><surname>Basch</surname></persName>
		</author>
		<idno type="DOI">10.1200/jco.2015.63.0830</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Q7YhtS2">J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page">557</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Basch, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J. Clin. Oncol. 34, 557 (2016).</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_hj5k6gn">Randomized trial of text messaging (TM) to reduce early discontinuation of aromatase inhibitor (AI) therapy in women with breast cancer: SWOG S1105</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Hershman</surname></persName>
		</author>
		<idno type="DOI">10.1200/jco.2019.37.15_suppl.6516</idno>
	</analytic>
	<monogr>
		<title level="m" xml:id="_fAHYtB2">Oral presentation at: 2019 ASCO Annual Meeting</title>
		<imprint>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hershman, D. L. et al. Randomized trial of text messaging (TM) to reduce early discontinuation of aromatase inhibitor (AI) therapy in women with breast can- cer: SWOG S1105. Oral presentation at: 2019 ASCO Annual Meeting (2019).</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_RvYMVP7">WellDoc™ Mobile diabetes management randomized controlled trial: change in clinical and behavioral outcomes and patient and physician satisfaction</title>
		<author>
			<persName><surname>Quinn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_QcHesCk">Diab. Tech. Therap</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="160" to="168" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Quinn, et al. WellDoc™ Mobile diabetes management randomized controlled trial: change in clinical and behavioral outcomes and patient and physician satisfaction. Diab. Tech. Therap. 10, 160-168 (2008).</note>
</biblStruct>

<biblStruct xml:id="b31">
	<monogr>
		<title level="m" type="main" xml:id="_GBn5SQu">Digital Tumor Board Solutions have significant impact on case preparation</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Hammer</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note type="report_type">JCO Clinical Cancer Informatics</note>
	<note>forthcoming</note>
	<note type="raw_reference">Hammer, R. D. et al. Digital Tumor Board Solutions have significant impact on case preparation. JCO Clinical Cancer Informatics (forthcoming).</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_etqxZZW">Study protocol for Young &amp; Strong: a cluster randomized design to increase attention to unique issues faced by young women with newly diagnosed breast cancer</title>
		<author>
			<persName><surname>Greaney</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9cUa9se">BMC Public Health</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Greaney, et al. Study protocol for Young &amp; Strong: a cluster randomized design to increase attention to unique issues faced by young women with newly diagnosed breast cancer. BMC Public Health. 15, 1-11 (2015).</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_MEpSHZb">Impact of availability of telehealth programs on documented HIV viral suppression: A Cluster-Randomized Program Evaluation in the Veterans Health Administration</title>
		<author>
			<persName><surname>Ohl</surname></persName>
		</author>
		<idno type="DOI">10.1093/ofid/ofz206</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RhTkkd6">Open Forum Infect Dis</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">206</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ohl, et al. Impact of availability of telehealth programs on documented HIV viral suppression: A Cluster-Randomized Program Evaluation in the Veterans Health Administration. Open Forum Infect Dis. 6, ofz206 (2019).</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_PetzeHg">The use of the cluster randomized crossover design in clinical trials: protocol for a systematic review</title>
		<author>
			<persName><surname>Arnup</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SvAA4Ek">Syst. Rev</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="1" to="6" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Arnup, et al. The use of the cluster randomized crossover design in clinical trials: protocol for a systematic review. Syst. Rev. 3, 1-6 (2014).</note>
</biblStruct>

<biblStruct xml:id="b35">
	<monogr>
		<title level="m" type="main" xml:id="_DJqqsRW">A Practical Guide to Cluster Randomised Trials in Health Services Research</title>
		<author>
			<persName><forename type="first">S</forename><surname>Eldridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kerry</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2012">2012</date>
			<publisher>John Wiley &amp; Sons</publisher>
			<biblScope unit="volume">120</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">Eldridge, S. &amp; Kerry, S. A Practical Guide to Cluster Randomised Trials in Health Services Research. Vol. 120 (John Wiley &amp; Sons, 2012).</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_RREyBfY">Pitfalls of and controversies in cluster randomization trials</title>
		<author>
			<persName><forename type="first">A</forename><surname>Donner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Klar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ANsDA7m">Am. J. Public Health</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="416" to="422" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Donner, A. &amp; Klar, N. Pitfalls of and controversies in cluster randomization trials. Am. J. Public Health 94, 416-422 (2004).</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_ARwmEJX">Design and interpretation of vaccine field studies</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Halloran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4DvgwUe">Epidemiol. Rev</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="73" to="88" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Halloran, M. E. et al. Design and interpretation of vaccine field studies. Epidemiol. Rev. 21, 73-88 (1999).</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_H4hacv8">Randomization by group: a formal analysis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Cornfield</surname></persName>
		</author>
		<idno type="DOI">10.1093/oxfordjournals.aje.a112592</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6uWjyeF">Am. J. Epidemiol</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="100" to="102" />
			<date type="published" when="1978">1978</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cornfield, J. Randomization by group: a formal analysis. Am. J. Epidemiol. 108, 100-102 (1978).</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_dwF5bwE">Contamination in trials: is cluster randomisation the answer?</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Torgerson</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.322.7282.355</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TM2VGSd">BMJ</title>
		<imprint>
			<biblScope unit="volume">322</biblScope>
			<biblScope unit="page" from="355" to="357" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Torgerson, D. J. Contamination in trials: is cluster randomisation the answer?. BMJ 322, 355-357 (2001).</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_3EcznkQ">Cluster Randomized Trials: opportunities and Barriers Identified by Leaders of Eight Health Plans</title>
		<author>
			<persName><forename type="first">K</forename><surname>Mazor</surname></persName>
		</author>
		<idno type="DOI">10.1097/mlr.0b013e31806728c4</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2UCW8aE">Med. Care. S</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page">37</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mazor, K. et al. Cluster Randomized Trials: opportunities and Barriers Identified by Leaders of Eight Health Plans. Med. Care. S29-S37 (2007).</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main" xml:id="_5mMvfs3">Statistical analysis and optimal design for cluster randomized trials</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Raudenbush</surname></persName>
		</author>
		<idno type="DOI">10.1037//1082-989x.2.2.173</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wyBMpYA">Psychol. methods</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">173</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Raudenbush, S. W. Statistical analysis and optimal design for cluster randomized trials. Psychol. methods 2, 173 (1997).</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_BrT8ahg">Analysis of cluster randomized trials in primary care: a practical approach</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Campbell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vxdG3Pc">Family Pract</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="192" to="196" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Campbell, M. K. et al. Analysis of cluster randomized trials in primary care: a practical approach. Family Pract. 17, 192-196 (2000).</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main" xml:id="_jhFqqbg">Micro-Randomized Trials: an experimental design for developing just-in-time adaptive interventions</title>
		<author>
			<persName><forename type="first">P</forename><surname>Klasnja</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_69Du3nJ">Health Psychol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1220" to="1228" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Klasnja, P. et al. Micro-Randomized Trials: an experimental design for developing just-in-time adaptive interventions. Health Psychol. 34, 1220-1228 (2015).</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main" xml:id="_s6yQMxk">Efficacy of contextually tailored suggestions for physical activity: a Micro-randomized Optimization Trial of HeartSteps</title>
		<author>
			<persName><forename type="first">P</forename><surname>Klasnja</surname></persName>
		</author>
		<idno type="DOI">10.1093/abm/kay067</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bGJmRFv">Ann. Behav. Med</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="573" to="582" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Klasnja, P. et al. Efficacy of contextually tailored suggestions for physical activity: a Micro-randomized Optimization Trial of HeartSteps. Ann. Behav. Med. 53, 573-582 (2018).</note>
</biblStruct>

<biblStruct xml:id="b45">
	<monogr>
		<author>
			<persName><forename type="first">Laurenceau</forename><surname>Bolger</surname></persName>
		</author>
		<title level="m" xml:id="_FS9n6x5">Intensive Longitudinal Methods: An Introduction to Diary and Experience Sampling Research</title>
		<imprint>
			<publisher>Guilford Press</publisher>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bolger &amp; Laurenceau. Intensive Longitudinal Methods: An Introduction to Diary and Experience Sampling Research (Guilford Press, 2013).</note>
</biblStruct>

<biblStruct xml:id="b46">
	<monogr>
		<author>
			<persName><forename type="first">&amp;</forename><surname>Walls</surname></persName>
		</author>
		<author>
			<persName><surname>Schafer</surname></persName>
		</author>
		<idno type="DOI">10.1093/acprof:oso/9780195173444.001.0001</idno>
		<title level="m" xml:id="_ZjwANeR">Models for intensive longitudinal data</title>
		<imprint>
			<publisher>Oxford University Press</publisher>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Walls &amp; Schafer. Models for intensive longitudinal data (Oxford University Press, 2006).</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main" xml:id="_uqgDhQx">Clinical trial structures</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Evans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Baz6w9q">J. Exp. Stroke Transl. Med</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="8" to="18" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Evans, S. R. Clinical trial structures. J. Exp. Stroke Transl. Med. 3, 8-18 (2010).</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main" xml:id="_jSTasxc">How we design feasibility studies</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Bowen</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.amepre.2009.02.002</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WQBJN3M">Am. J. Prev. Med</title>
		<imprint>
			<biblScope unit="page" from="452" to="457" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bowen, D. J. et al. How we design feasibility studies. Am. J. Prev. Med. 452-457 (2009).</note>
</biblStruct>

<biblStruct xml:id="b49">
	<monogr>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Dimitrov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Rumrill</surname></persName>
		</author>
		<idno type="DOI">10.3233/wor-2003-00285</idno>
		<title level="m" xml:id="_UqADPUY">Pretest-posttest Designs and Measurement of Change</title>
		<imprint>
			<publisher>IOS Press</publisher>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dimitrov, D. M. &amp; Rumrill, P. D. Pretest-posttest Designs and Measurement of Change. (IOS Press, 2003).</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main" xml:id="_G7t9DCR">How effective are clinical pathways with and without online peer-review? An analysis of bone metastases pathway in a large, integrated National Cancer Institute-Designated Comprehensive Cancer Center Network</title>
		<author>
			<persName><forename type="first">S</forename><surname>Beriwal</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ijrobp.2011.09.056</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_feTttt6">Int. J. Radiat. Oncol. Biol. Phys</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="1246" to="1251" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Beriwal, S. et al. How effective are clinical pathways with and without online peer-review? An analysis of bone metastases pathway in a large, integrated National Cancer Institute-Designated Comprehensive Cancer Center Network. Int. J. Radiat. Oncol. Biol. Phys. 83, 1246-1251 (2012).</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main" xml:id="_vpuaQXm">Physicians&apos; attitudes towards the advice of a guideline-based decision support system: a case study with OncoDoc2 in the Management of Breast Cancer Patients</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bouaud</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TmAJHMZ">Stud. Health Technol. Inform</title>
		<imprint>
			<biblScope unit="page" from="264" to="269" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bouaud, J. et al. Physicians&apos; attitudes towards the advice of a guideline-based decision support system: a case study with OncoDoc2 in the Management of Breast Cancer Patients. Stud. Health Technol. Inform. 264-269 (2015).</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main" xml:id="_H6bPe9A">Non-intercepted dose errors in prescribing anti-neoplastic treatment: a prospective, comparative cohort study</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">O</forename><surname>Mattsson</surname></persName>
		</author>
		<idno type="DOI">10.1093/annonc/mdv032</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qwtEcB4">Ann. Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="981" to="986" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mattsson, T. O. et al. Non-intercepted dose errors in prescribing anti-neoplastic treatment: a prospective, comparative cohort study. Ann. Oncol. 26, 981-986 (2015).</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main" xml:id="_HuuFg5e">Enhancing patient-provider communication with the electronic self-report assessment for cancer: a randomized trial</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Berry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kwvRs5y">J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1029" to="1035" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Berry, D. L. et al. Enhancing patient-provider communication with the electronic self-report assessment for cancer: a randomized trial. J. Clin. Oncol. 29, 1029-1035 (2011).</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main" xml:id="_JvtmY5w">Influence of sanitizing methods on healthcare-associated infections onset: a multicentre, randomized, controlled pre-post interventional study</title>
		<author>
			<persName><forename type="first">E</forename><surname>Caselli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_yQfCqSU">J. Clin. Trials</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="1" to="6" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Caselli, E. et al. Influence of sanitizing methods on healthcare-associated infections onset: a multicentre, randomized, controlled pre-post interventional study. J. Clin. Trials. 6, 1-6 (2016).</note>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main" xml:id="_BggenMv">Retrospective clinical studies in surgery: potentials and pitfalls</title>
		<author>
			<persName><forename type="first">S</forename><surname>Sauerland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_v3DrGXx">J. Hand Surg. Br</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="117" to="121" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sauerland, S. et al. Retrospective clinical studies in surgery: potentials and pit- falls. J. Hand Surg. Br. 27, 117-121 (2002).</note>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main" xml:id="_hZrg7s9">Looking through the retrospectoscope: reducing bias in emergency medicine chart review studies</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Kaji</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6HUDdnQ">Ann. Emerg. Med</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="292" to="298" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kaji, A. H. et al. Looking through the retrospectoscope: reducing bias in emer- gency medicine chart review studies. Ann. Emerg. Med. 64, 292-298 (2014).</note>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main" xml:id="_Q3KcfbU">Threats to validity in retrospective studies</title>
		<author>
			<persName><forename type="first">C</forename><surname>Tofthagen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zUs63Zm">J. Adv. Pract. Oncol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">181</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tofthagen, C. Threats to validity in retrospective studies. J. Adv. Pract. Oncol. 3, 181 (2012).</note>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main" xml:id="_pcZWKM6">Adjusting for selection bias in retrospective, case-control studies</title>
		<author>
			<persName><forename type="first">S</forename><surname>Geneletti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_YV2FT4E">Biostatistics</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="17" to="31" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Geneletti, S. et al. Adjusting for selection bias in retrospective, case-control studies. Biostatistics 10, 17-31 (2009).</note>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main" xml:id="_MsVrFBe">Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Somashekhar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rhUrfYz">Ann. Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="418" to="423" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Somashekhar, S. P. et al. Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board. Ann. Oncol. 29, 418-423 (2018).</note>
</biblStruct>

<biblStruct xml:id="b60">
	<monogr>
		<author>
			<persName><forename type="first">R</forename><surname>Graham</surname></persName>
		</author>
		<idno type="DOI">10.17226/13058</idno>
		<title level="m" xml:id="_EnnMrPb">Clinical Practice Guidelines We Can Trust: Committee on Standards for Developing Trustworthy Clinical Practice Guidelines</title>
		<imprint>
			<publisher>National Academies Press</publisher>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Graham, R. et al. Clinical Practice Guidelines We Can Trust: Committee on Stan- dards for Developing Trustworthy Clinical Practice Guidelines. (National Academies Press, 2011).</note>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main" xml:id="_5PtT8tT">ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology. American Heart Association Task Force on Practice Guidelines</title>
		<author>
			<persName><surname>Goff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8UNdWte">Circulation</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="2935" to="2959" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Goff, et al. ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology. American Heart Association Task Force on Practice Guidelines. Circulation 63, 2935-2959 (2014).</note>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main" xml:id="_JjdEf59">Guideline Development Group Risk assessment of fragility fractures: summary of NICE guidance</title>
		<author>
			<persName><forename type="first">S</forename><surname>Rabar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KG3JsuR">BMJ</title>
		<imprint>
			<biblScope unit="volume">345</biblScope>
			<biblScope unit="page">3698</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rabar, S. et al. Guideline Development Group Risk assessment of fragility frac- tures: summary of NICE guidance. BMJ 345, p.e3698 (2012).</note>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main" xml:id="_aVqWraa">Reporting and methods in clinical prediction research: a systematic review</title>
		<author>
			<persName><forename type="first">W</forename><surname>Bouwmeester</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pmed.1001221</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_sbUMVne">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">1001221</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bouwmeester, W. et al. Reporting and methods in clinical prediction research: a systematic review. PLoS Med. 9, e1001221 (2012).</note>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main" xml:id="_ckYb2Vz">Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Collins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_PK3qVbv">Ann. Intern. Med</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="page" from="211" to="219" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Collins, G. S. et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann. Intern. Med. 131, 211-219 (2015).</note>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main" xml:id="_b8mQA25">A guide to systematic review and meta-analysis of prediction model performance</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Debray</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FTFthbv">BMJ</title>
		<imprint>
			<biblScope unit="volume">356</biblScope>
			<biblScope unit="page">6460</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Debray, T. P. et al. A guide to systematic review and meta-analysis of prediction model performance. BMJ 356, i6460 (2017).</note>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main" xml:id="_HShqg7k">Beyond &quot;implementation&quot;: digital health innovation and service design</title>
		<author>
			<persName><forename type="first">J</forename><surname>Shaw</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_QcRYCQq">NPJ Digit. Med</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="1" to="5" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shaw, J. et al. Beyond &quot;implementation&quot;: digital health innovation and service design. NPJ Digit. Med. 1, 1-5 (2018).</note>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main" xml:id="_2zkDFkU">Computerized clinical decision support for prescribing: provision does not guarantee uptake</title>
		<author>
			<persName><surname>Moxey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_M2BUyKN">J. Am. Med. Inform. Associat</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="25" to="33" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Moxey, et al. Computerized clinical decision support for prescribing: provision does not guarantee uptake. J. Am. Med. Inform. Associat. 17, 25-33 (2010).</note>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main" xml:id="_xAQPmjz">Decision time for clinical decision support systems</title>
		<author>
			<persName><surname>O'sullivan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JaYks3A">Clin. Med</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">338</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">O&apos;Sullivan, et al. Decision time for clinical decision support systems. Clin. Med. 14, 338 (2014).</note>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main" xml:id="_DQ3VrWU">Good Clinical Practice Guidance and Pragmatic Clinical Trials: balancing the best of both worlds</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Mentz</surname></persName>
		</author>
		<idno type="DOI">10.1161/circulationaha.115.019902</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bzA2SMZ">Circulation</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="872" to="880" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mentz, R. J. et al. Good Clinical Practice Guidance and Pragmatic Clinical Trials: balancing the best of both worlds. Circulation 133, 872-880 (2016).</note>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main" xml:id="_xXHcdYV">Pragmatic trials</title>
		<author>
			<persName><forename type="first">I</forename><surname>Ford</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zePW32r">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="page" from="454" to="463" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ford, I. et al. Pragmatic trials. N. Engl. J. Med. 375, 454-463 (2016).</note>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main" xml:id="_AKS6Rg9">An efficient basket trial design</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Cunanan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_dSJNB8U">Stat. Med</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="1568" to="1579" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cunanan, K. M. et al. An efficient basket trial design. Stat. Med. 36, 1568-1579 (2017).</note>
</biblStruct>

<biblStruct xml:id="b72">
	<monogr>
		<title level="m" type="main" xml:id="_JRBaJS4">Modeling and Simulation in the Context of Health Technology Assessment: Review of Existing Guidance, Future Research Needs, and Validity Assessment</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">J</forename><surname>Dahabreh</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dahabreh, I. J. et al. Modeling and Simulation in the Context of Health Technology Assessment: Review of Existing Guidance, Future Research Needs, and Validity Assessment (2017).</note>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main" xml:id="_mcDRuq3">Evaluation in health informatics: computer simulation</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Anderson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UU9mRF7">Comput. Biol. Med</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="151" to="164" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Anderson, J. G. et al. Evaluation in health informatics: computer simulation. Comput. Biol. Med. 32, 151-164 (2002).</note>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main" xml:id="_VKCB4pb">Systems modeling and simulation applications for critical care medicine</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Dong</surname></persName>
		</author>
		<idno type="DOI">10.1186/2110-5820-2-18</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RvhHP5m">Ann. Intensive Care</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dong, Y. et al. Systems modeling and simulation applications for critical care medicine. Ann. Intensive Care 2, 1-10 (2012).</note>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main" xml:id="_keYwWDj">Tutorial on the simulation of healthcare systems</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Roberts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m" xml:id="_f5p9wK3">Proceedings of the 2011 winter simulation conference (wsc)</title>
		<meeting>the 2011 winter simulation conference (wsc)</meeting>
		<imprint>
			<date type="published" when="2011">2011</date>
			<biblScope unit="page" from="1403" to="1414" />
		</imprint>
	</monogr>
	<note type="raw_reference">Roberts, S. D. Tutorial on the simulation of healthcare systems. Proceedings of the 2011 winter simulation conference (wsc), 1403-1414 (2011).</note>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main" xml:id="_bc4UE7d">From usability testing to clinical simulations: bringing context into the design and evaluation of usable and safe health information technologies. Contribution of the IMIA human factors engineering for healthcare informatics working group</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kushniruk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4MpJWgj">Yearb. Med. Inform</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="78" to="85" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kushniruk A. et. al. From usability testing to clinical simulations: bringing con- text into the design and evaluation of usable and safe health information technologies. Contribution of the IMIA human factors engineering for health- care informatics working group. Yearb. Med. Inform. 22, 78-85 (2013).</note>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main" xml:id="_cDJMVV9">Low-cost rapid usability engineering: designing and customizing usable healthcare information systems</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Kushniruk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_V3aHrNT">Healthc, Q</title>
		<imprint>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kushniruk, A. W. et al. Low-cost rapid usability engineering: designing and customizing usable healthcare information systems. Healthc, Q. (2006).</note>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main" xml:id="_shPyzyH">Low-Cost Rapid Usability Testing for health information systems: is it worth the effort? Stud</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">B</forename><surname>Baylis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_yT6AkMj">Health Technol. Inform</title>
		<imprint>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Baylis, T. B. et al. Low-Cost Rapid Usability Testing for health information sys- tems: is it worth the effort? Stud. Health Technol. Inform. (2012).</note>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main" xml:id="_mkEHCDY">Research and design on distributed remote simulation based on Web</title>
		<author>
			<persName><forename type="first">H</forename><surname>Yao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m" xml:id="_w22NXB2">IEEE International Conference on Information Management and Engineering</title>
		<imprint>
			<date type="published" when="2010">2010</date>
			<biblScope unit="page" from="522" to="525" />
		</imprint>
	</monogr>
	<note type="raw_reference">Yao, H. et al. Research and design on distributed remote simulation based on Web. In IEEE International Conference on Information Management and Engi- neering. pp. 522-525 (2010).</note>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main" xml:id="_AQnKnYS">Clinical simulation: a method for development and evaluation of clinical information systems</title>
		<author>
			<persName><forename type="first">S</forename><surname>Jensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_dRb4M83">J. Biomed. Inform</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="65" to="76" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jensen, S. et al. Clinical simulation: a method for development and evaluation of clinical information systems. J. Biomed. Inform. 54, 65-76 (2015).</note>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main" xml:id="_t5xccT6">Integrating usability testing and think-aloud protocol analysis with &quot;near-live&quot; clinical simulations in evaluating clinical decision support</title>
		<author>
			<persName><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ijmedinf.2012.02.009</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_R56We3P">Int. J. Med. Inform</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page" from="761" to="772" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Li, et al. Integrating usability testing and think-aloud protocol analysis with &quot;near-live&quot; clinical simulations in evaluating clinical decision support. Int. J. Med. Inform. 81, 761-772 (2012).</note>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main" xml:id="_YYAJ3gH">Association of the usability of electronic health records with cognitive workload and performance levels among physicians</title>
		<author>
			<persName><surname>Mazur</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamanetworkopen.2019.1709</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hKCUzjQ">JAMA Netw Open</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="191709" to="e191709" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mazur, et al. Association of the usability of electronic health records with cog- nitive workload and performance levels among physicians. JAMA Netw Open. 2, e191709-e191709 (2019).</note>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main" xml:id="_WEugpXH">A mixed methods study for the evaluation of a digital health solution for cancer multidisciplinary team meetings using simulation-based research methods</title>
		<author>
			<persName><surname>Gardner</surname></persName>
		</author>
		<idno type="DOI">10.1200/jco.2020.38.15_suppl.e14063</idno>
	</analytic>
	<monogr>
		<title level="m" xml:id="_GcbARFj">ASCO 2020 Annual Conference</title>
		<imprint>
			<publisher>American Society of Clinical Oncology</publisher>
			<date type="published" when="2020">2020</date>
			<biblScope unit="page">14063</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">Gardner, et al. A mixed methods study for the evaluation of a digital health solution for cancer multidisciplinary team meetings using simulation-based research methods. ASCO 2020 Annual Conference. American Society of Clinical Oncology. pp. e14063 (2020)</note>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main" xml:id="_tCwjKNR">Real-world data for clinical evidence generation in oncology</title>
		<author>
			<persName><surname>Khozin</surname></persName>
		</author>
		<idno type="DOI">10.1093/jnci/djx187</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3j8af5n">J. Natl. Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="page">187</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Khozin, et al. Real-world data for clinical evidence generation in oncology. J. Natl. Cancer Inst. 109, djx187 (2017).</note>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main" xml:id="_KQF75nP">Open triple therapy for chronic obstructive pulmonary disease: Patterns of prescription, exacerbations and healthcare costs from a large Italian claims database</title>
		<author>
			<persName><surname>Calabria</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.pupt.2020.101904</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wqY8865">Pulmon. Pharmacol. Therap</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page">101904</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Calabria, et al. Open triple therapy for chronic obstructive pulmonary disease: Patterns of prescription, exacerbations and healthcare costs from a large Italian claims database. Pulmon. Pharmacol. Therap. 61, 101904 (2020).</note>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main" xml:id="_kAuYQnF">Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database</title>
		<author>
			<persName><surname>Pal</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12885-019-5716-z</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_W8pv6fN">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page">548</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pal, et al. Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. BMC Cancer 19, 548 (2019).</note>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main" xml:id="_mEy8TD8">Evaluation of the quality of prognosis studies in systematic reviews</title>
		<idno type="DOI">10.1109/etis64005.2025.10961721</idno>
		<ptr target="https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-software" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_P32UBzp">Ann. Intern. Med</title>
		<imprint>
			<biblScope unit="volume">144</biblScope>
			<biblScope unit="page">102</biblScope>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-170921-samd-n41- clinical-evaluation_1.pdf. 100. https://www.fda.gov/medical-devices/software-medical-device-samd/artificial- intelligence-and-machine-learning-software-medical-device. 101. Hayden, et al. Evaluation of the quality of prognosis studies in systematic reviews. Ann. Intern. Med. 144, 427-437 (2006). 102</note>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main" xml:id="_ZfEdgCF">PROBAST: a tool to assess the risk of bias and applicability of prediction model studies</title>
		<author>
			<persName><surname>Higgins</surname></persName>
		</author>
		<ptr target="https://www.iso.org/standard/74438.html.113" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_5xb7vCb">Ann. Intern. Med</title>
		<imprint>
			<biblScope unit="volume">343</biblScope>
			<biblScope unit="page">105</biblScope>
			<date type="published" when="2006">2011. 2016. 2019. 2006</date>
		</imprint>
	</monogr>
	<note>The Cochrane Collaboration&apos;s tool for assessing risk of bias in randomised trials BMJ ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions BMJ</note>
	<note type="raw_reference">Higgins, et al. The Cochrane Collaboration&apos;s tool for assessing risk of bias in randomised trials. BMJ 343, d5928 (2011). 103. Sterne, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355 (2016). 104. Wolff, et al. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Ann. Intern. Med. 170, 51-58 (2019). 105. https://webstore.iec.ch/preview/info_iec62304%7bed1.0%7den_d.pdf. (2006). 106. ISO. https://www.iso.org/standard/52823.html. 107. ISO. https://www.iso.org/standard/51344.html. 108. ISO. https://www.iso.org/standard/57757.html. 109. FDA. https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/21st- century-cures-act. 110. https://www.eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32017R074 6&amp;from=DE. 111. ISO. https://www.iso.org/standard/63553.html. 112. ISO. https://www.iso.org/standard/74438.html. 113</note>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main" xml:id="_kA95Ysw">Mobile health intervention for self-management of adolescent chronic pain (WebMAP mobile): Protocol for a hybrid effectivenessimplementation cluster randomized controlled trial</title>
		<author>
			<persName><surname>Denis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kaGjR5M">Contemp. Clin. Trials</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">116</biblScope>
			<date type="published" when="2017">2017. 2019. 2018</date>
		</imprint>
	</monogr>
	<note>Randomized Trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients Nature Digit. Med. Evaluation of a digitally-enabled care pathway for acute kidney injury management in hospital emergency admissions J. Natl. Cancer Inst.</note>
	<note type="raw_reference">Denis, et al. Randomized Trial comparing a web-mediated follow-up with rou- tine surveillance in lung cancer patients. J. Natl. Cancer Inst. 109 (2017). 114. Connell, et al. Evaluation of a digitally-enabled care pathway for acute kidney injury management in hospital emergency admissions. Nature Digit. Med. 2, 1-9 (2019). 115. Palermo, et al. Mobile health intervention for self-management of adolescent chronic pain (WebMAP mobile): Protocol for a hybrid effectiveness- implementation cluster randomized controlled trial. Contemp. Clin. Trials. 74, 55-60 (2018). 116</note>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main" xml:id="_HgX8fmt">Effectiveness of digital medicines to improve clinical outcomes in patients with uncontrolled hypertension and type 2 diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial</title>
		<author>
			<persName><surname>Frias</surname></persName>
		</author>
		<idno type="DOI">10.2196/jmir.7833</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UDsg7xp">J. Med. Internet Res</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page">117</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Frias, et al. Effectiveness of digital medicines to improve clinical outcomes in patients with uncontrolled hypertension and type 2 diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial. J. Med. Internet Res. 19, e246 (2017). 117</note>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main" xml:id="_NJ78qe7">Reduction in chemotherapy order errors with computerised physician order entry and clinical decision support systems</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Aziz</surname></persName>
		</author>
		<idno type="DOI">10.1177/183335831504400303</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SAy758C">Health Inf. Manag</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page">118</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Aziz, M. T. et al. Reduction in chemotherapy order errors with computerised physician order entry and clinical decision support systems. Health Inf. Manag 44, 13-22 (2015). 118</note>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main" xml:id="_GDZ2KPm">Computerized provider order entry in pediatric oncology: design, implementation, and outcomes</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1200/jop.2011.000344</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jhWPvXz">J Oncol Pract</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">119</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chen, A. R. et al. Computerized provider order entry in pediatric oncology: design, implementation, and outcomes. J Oncol Pract. 7, 218-222 (2011). 119</note>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main" xml:id="_nU9RuG6">Simulation studies for the evaluation of health information technologies: experiences and results</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wu</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41467-018-06799-6</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vg8qFUr">Health Inf. Manag. J</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">121</biblScope>
			<date type="published" when="2012">2018. 2012</date>
		</imprint>
	</monogr>
	<note>Master clinical medical knowledge at certificated doctor-level with deep learning model Nat. Commun.</note>
	<note type="raw_reference">Wu, J. et al. Master clinical medical knowledge at certificated doctor-level with deep learning model. Nat. Commun. 9, 4352 (2018). 120. Ammenwerth, et al. Simulation studies for the evaluation of health information technologies: experiences and results. Health Inf. Manag. J. 41, 14-21 (2012). 121</note>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main" xml:id="_n73bnYM">Utility of a clinical decision support system in weight loss prediction after head and neck cancer radiotherapy</title>
		<author>
			<persName><surname>Cheng</surname></persName>
		</author>
		<idno type="DOI">10.1200/cci.18.00058</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Ye4SJmg">JCO Clin. Cancer Inform</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">122</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cheng, et al. Utility of a clinical decision support system in weight loss prediction after head and neck cancer radiotherapy. JCO Clin. Cancer Inform. 3, 1-11 (2018). 122</note>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main" xml:id="_UqfURb9">Do you understand the words that are comin outta my mouth? Voice assistant comprehension of medication names</title>
		<author>
			<persName><surname>Palanica</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41746-019-0133-x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RF64B2R">Nat. Digit. Med</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">123</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Palanica, et al. Do you understand the words that are comin outta my mouth? Voice assistant comprehension of medication names. Nat. Digit. Med. 2, 1-6 (2019). 123</note>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main" xml:id="_mzydD4Q">Do high symptom scores trigger clinical actions? An audit after implementing symptom screening</title>
		<author>
			<persName><forename type="first">H</forename><surname>Seow</surname></persName>
		</author>
		<idno type="DOI">10.1200/jop.2011.000525</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BZnFsnk">J. Oncol. Pract</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="142" to="e148" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Seow, H. et al. Do high symptom scores trigger clinical actions? An audit after implementing symptom screening. J. Oncol. Pract. 8, e142-e148 (2012).</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
